

Vulvar Cancer Guidelines

Complete report



TABLE OF CONTENTS

1	Introduction.....	4
2	Acknowledgements	4
3	Method.....	4
3.1	Nomination of multidisciplinary international development group	4
3.2	Identification of scientific evidence	5
3.3	Formulation of guidelines.....	5
3.4	External evaluation of the guidelines - International review.....	6
3.5	Integration of international reviewers comments	6
4	Management of conflicts of interest.....	6
5	Summary of guidelines	7
5.1	Diagnosis and referral	7
5.2	Staging system	7
5.3	Preoperative investigations	7
5.4	Surgical management.....	8
5.5	Sentinel lymph node procedure.....	9
5.6	Radiation therapy.....	9
5.7	Chemoradiation.....	10
5.8	Systemic treatment.....	10
5.9	Treatment of recurrent disease	10
5.10	Follow-up	11
6	Diagnosis and referral	12
6.1	Summary of available scientific evidence.....	12
6.2	Previous initiatives.....	12
6.3	Development group comments	12
6.4	Guidelines	12
7	Staging system.....	13
7.1	Summary of available scientific evidence.....	13
7.2	Previous initiatives.....	13
7.3	Development group comments	13
7.4	Guidelines.....	13
8	Preoperative investigations	15
8.1	Summary of available scientific evidence.....	15
8.2	Previous initiatives.....	16
8.3	Development group comments	16
8.4	Guidelines	17
9	Surgical management	20
9.1	Summary of available scientific evidence.....	20
9.2	Previous initiatives.....	24
9.3	Development group comments	24
9.4	Guidelines	25
10	Sentinel lymph node procedure	26
10.1	Summary of available scientific evidence.....	26
10.2	Previous initiatives.....	29

10.3	Development group comments	30
10.4	Guidelines	30
11	Radiation therapy	32
11.1	Summary of available scientific evidence.....	32
11.2	Previous initiatives.....	33
11.3	Development group comments	34
11.4	Guidelines.....	34
12	Chemoradiation	36
12.1	Summary of available scientific evidence.....	36
12.2	Previous initiatives.....	38
12.3	Development group comments	38
12.4	Guidelines.....	38
13	Systemic treatment	44
13.1	Summary of available scientific evidence.....	44
13.2	Previous initiatives.....	44
13.3	Development group comments	44
13.4	Guidelines.....	44
14	Treatment of recurrent disease.....	46
14.1	Summary of available scientific evidence.....	46
14.2	Previous initiatives.....	46
14.3	Development group comments	46
14.4	Guidelines.....	46
15	Follow-up.....	49
15.1	Summary of available scientific evidence.....	49
15.2	Previous initiatives.....	49
15.3	Development group comments	49
15.4	Guidelines.....	49
16	Acronyms and abbreviations	50
17	References.....	52
18	Appendices	67
18.1	Appendix 1 - List of the international development group	67
18.2	Appendix 2 - List of evidence-based medicine websites consulted	68
18.3	Appendix 3 - Key to evidence statements and grades of recommendations.....	69

1 Introduction

Vulvar cancers are relatively uncommon and affect predominantly elderly women. The vast majority are squamous cell carcinomas. The objectives of the guidelines are to improve and to homogenize the management of patients with vulvar cancer. The guideline is intended for use by gynaecological oncologists, general gynaecologists, surgeons, pathologists, radiotherapists, medical and clinical oncologists, general practitioners, palliative care teams, and allied health professionals.

The guideline covers diagnosis and referral, preoperative investigations, surgical management local treatment, groin treatment, reconstructive surgery, sentinel lymph node procedure, radiation therapy, chemoradiation, systemic treatment, treatment of recurrent disease vulvar recurrence, groin recurrence, distant metastases, and follow-up for patients with vulvar cancer and provides information for discussion with patients and carers. This complete report does not include any economic analysis of the strategies. These guidelines apply to adults over the age of 18 years with squamous cell carcinoma of the vulva. These guidelines do not address patients with other vulvar cancer histologies.

Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment.

2 Acknowledgements

The European society of gynaecological oncology ESGO would like to thank the international development group for their constant availability, work, and for making possible the development of these guidelines for the management of patients with vulvar cancer. ESGO also wishes to express sincere gratitude to the Institut national du cancer INCa, France for providing the main funding for this work.

3 Method

The guidelines were developed using a five-step process see figure 1 . The strengths of the process include creation of a multidisciplinary international development group, use of scientific evidence and/or international expert consensus to support the guidelines, use of an international external review process physicians and patients , and management of potential conflicts of interests. This development process involved two meetings of the international development group, chaired by Professor Ate van der Zee and Dr Maaike Oonk University Medical Center Groningen, Netherlands.



Figure 1. Development process

3.1 Nomination of multidisciplinary international development group

The ESGO Council nominated practicing clinicians that care for vulvar cancer patients and have demonstrated leadership in clinical management of patients through research, administrative responsibilities, and/or committee

membership to serve on the expert panel. The objective was to assemble a multidisciplinary panel. It was therefore essential to include professionals from relevant disciplines gynaecological oncology, medical oncology, pathology, radiation oncology, surgery so that their perspectives would contribute to the validity and acceptability of the guidelines. The list of the development group is available in Appendix 1.

3.2 Identification of scientific evidence

To ensure that the statements made in this document are evidence based, the current literature was reviewed and critically appraised. A systematic literature review of the studies published between January 1980 and September 2015 was carried out using the MEDLINE database. This search used indexing terms as follows: accuracy, adverse effects, bilateral en bloc dissection, biopsy, chemotherapy primary, neoadjuvant, adjuvant), chemoradiation primary, neoadjuvant, adjuvant), chemotherapeutic agents, detection rate, diagnosis, en bloc dissection, exenteration anterior, posterior, total), follow -up, frozen sections, groin lymph node involvement, groin node metastasis, histology, histological examination, imaging, inguinofemoral lymph node dissection, laboratory testing, local excision, lymph node dissection, lymphadenectomy, inguinofemoral or deep, inguinal or superficial, ipsilateral, pelvic, lympho -vascular invasion, margin, node dissection, operation, pathology, pathology report, pelvic-lymph node dissection, perioperative care, physical examination, postoperative complications, preoperative care, preoperative workup, quality of life, radiotherapy primary, neoadjuvant, adjuvant), radiation primary, neoadjuvant, adjuvant), radical local excision, reconstructive surgery, sensibility, sentinel lymph node assessment, sentinel lymph node biopsy, sentinel lymph node dissection, specificity, staging, surgical management, surgical outcome, surgical procedures, surgical resection, surveillance, survival rate, survival analysis, systemic treatment, targeted therapy, toxicity, treatment outcome, tumour margin, vulvar cancer early and/or advanced stages, vulvectomy radical, simple, modified, hemi) .

The literature search was limited to publications in English. Priority was given to high-quality systematic reviews, meta-analyses, and randomized controlled trials but lower levels of evidence were also evaluated. The search strategy excluded editorials, letters, and *in vitro* studies. The reference list of each identified article was reviewed for other potentially relevant papers. The bibliography was also to be supplemented by additional references provided by the international development group.

Another bibliographic search was carried out to identify previous initiatives using a systematic literature search in MEDLINE database no restriction in the search period, indexing terms: clinical practice guidelines, evidence-based medicine, guidelines, methodology, recommendations, vulvar cancer and a bibliographic search using selected websites see Appendix 2 . All retrieved articles have been methodologically and clinically appraised. After the selection and critical appraisal of the articles, a summary of the scientific evidence has been developed.

3.3 Formulation of guidelines

During the first meeting December 4, 2015, the Development group developed guidelines for diagnosis and referral, preoperative investigations, surgical management local treatment, groin treatment, reconstructive surgery, sentinel lymph node procedure, radiation therapy, chemoradiation, systemic treatment, treatment of recurrent disease vulvar recurrence, groin recurrence, distant metastases, and follow -up.

The guidelines were retained if they were supported by sufficient high level scientific evidence and/or when a large consensus among experts was obtained. By default, a guideline is the clinical approach that is unanimously recognized by the Development group as being the criterion-standard clinical approach. If an approach is judged to be acceptable but is not unanimously recognized as a criterion-standard clinical approach, indication is given that it is still subject to discussion and/or evaluation. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group expert agreement). The reliability and quality of the evidence given throughout this document has been graded following the SIGN grading system see Appendix 3.

3.4 External evaluation of the guidelines - International review

The ESGO Council established a large panel of practicing clinicians that provide care to vulvar cancer patients and patients. The objective was to assemble a multidisciplinary panel. These international reviewers are independent from the development group. International reviewers are asked to evaluate each guideline according to their relevance and feasibility in clinical practice only physicians. Quantitative and qualitative evaluations of the guidelines are proposed to be performed. Patients will asked to qualitatively evaluate each guideline according their experience, preferences, feelings, etc..

3.5 Integration of international reviewers comments

Responses were be pooled and discussed by the international development group to finalize the guidelines.

4 Management of conflicts of interest

The experts of the multidisciplinary international development group were required to complete a declaration of interest form, and to promptly inform the ESGO council if any change in the disclosed information occurred during the course of this work.

5 Summary of guidelines

5.1 Diagnosis and referral


- ✓ In any patient suspected for vulvar cancer, diagnosis should be established by a punch/incision biopsy. Excision biopsy should be avoided for initial diagnosis, as this may obstruct further treatment planning.
- ✓ In patients with multiple vulvar lesions, all lesions should be biopsied separately with clear documentation of mapping.
- ✓ All patients with vulvar cancer should be referred to a Gynaecological oncology centre GOC and treated by a multidisciplinary gynaecological oncology team.

5.2 Staging system

- ✓ Vulvar cancer should be staged according to FIGO and/or TNM classification¹.

5.3 Preoperative investigations

- ✓ Preoperative work-up should at least include clear documentation of clinical exam size of lesion, distance to the midline/clitoris/anus/vagina/urethra and palpation of lymph nodes. Picture or clinical drawing is advised see below.



- ✓ Evaluation of the cervix/vagina/anus is recommended.
- C** Prior to sentinel lymph node biopsy, clinical examination and imaging of the groins either by ultrasound, positron emission tomography - computed tomography PET -CT, or magnetic resonance imaging MRI are required to identify potential lymph node metastases.
- ✓ Suspicious nodes at palpation and/or imaging should be analysed by fine -needle aspiration FNA or core biopsy when this would alter primary treatment.

¹ Throughout these recommendations advanced stage of disease is defined as clinical T3 and/or N3.

- ✓ Further staging with CT thorax/abdomen and pelvis is recommended where there is a clinical suspicion of, or proven nodal) metastatic disease and/or advanced stage disease.
- ✓ The pathology report on preoperative biopsy should at least include histological type and depth of invasion.

5.4 Surgical management

Local treatment

- C** Radical local excision is recommended.
- ✓ Consider additional, more superficial resection of differentiated vulvar intraepithelial neoplasia (VIN) in addition to radical local excision of invasive tumours.
- ✓ In multifocal invasive disease radical excision of each lesion as a separate entity may be considered. Vulvectomy may be required in cases with multifocal invasion arising on a background of extensive vulvar dermatosis.
- ✓ The goal of excision is to obtain tumour-free pathological margins. Surgical excision margins of at least 1 cm are advised. It is acceptable to consider less wide margins where the tumour lies close to midline structures clitoris, urethra, anus and preservation of their function is desired.
- ✓ When invasive disease extends to the pathological excision margins of the primary tumour, reexcision is treatment of choice.
- ✓ Advanced stage patients should be evaluated in a multidisciplinary setting to determine the optimal choice and order of treatment modalities.

Groin treatment

- C** Groin treatment should be performed for tumours > pT1a.
- B** For unifocal tumours < 4 cm without suspicious groin nodes on clinical examination and imaging any modality the sentinel lymph node procedure is recommended.
- C** For tumours ≥ 4 cm and/or in case of multifocal invasive disease inguinofemoral lymphadenectomy by separate incisions is recommended. In lateral tumours medial border > 1 cm from midline ipsilateral inguinofemoral lymphadenectomy is recommended. Contralateral inguinofemoral lymphadenectomy may be performed when ipsilateral nodes show metastatic disease.
- D** When lymphadenectomy is indicated, superficial and deep femoral nodes should be removed.
- C** Preservation of the saphenous vein is recommended.
- ✓ The optimal management of the groin full inguinofemoral lymphadenectomy or isolated removal only for enlarged, proven metastatic nodes remains to be defined.
- ✓ Where enlarged > 2 cm pelvic nodes are identified, their removal should be considered.

Reconstructive surgery

- ✓ Availability of reconstructive surgical skills as part of the multidisciplinary team is required in early as well as advanced stage disease.

5.5 Sentinel lymph node procedure

- B** The sentinel lymph node procedure is recommended in patients with unifocal cancers of < 4 cm, without suspicious groin nodes.
- B** Use of radioactive tracer is mandatory, use of blue dye is optional.
- C** Lymphoscintigram is advised to enable the preoperative identification, location and number of sentinel lymph nodes.
- C** Intraoperative evaluation and/or frozen sectioning of the sentinel lymph node can be performed in an attempt to prevent a second surgical procedure. Caution is warranted because of an increased risk of missing micrometastases on final pathology due to the loss of tissue arising from processing for frozen section assessment.
- ✓ When a sentinel lymph node is not found method failure, inguinofemoral lymphadenectomy should be performed.
- C** Where metastatic disease is identified in the sentinel lymph node any size: inguinofemoral lymphadenectomy in the groin with the metastatic sentinel lymph node.
- ✓ For tumours involving the midline: bilateral sentinel lymph node detection is mandatory. Where only unilateral sentinel lymph node detection is achieved, an inguinofemoral lymphadenectomy in the contralateral groin should be performed.
- C** Pathological evaluation of sentinel lymph nodes should include serial sectioning at levels of at least every 200 µm. If the H&E sections are negative, immunohistochemistry should be performed.

5.6 Radiation therapy

- ✓ Adjuvant radiotherapy should start as soon as possible, preferably within 6 weeks of surgical treatment.
- ✓ When invasive disease extends to the pathological excision margins of the primary tumour, and further surgical excision is not possible, postoperative radiotherapy should be performed.
- ✓ In case of close but clear pathological margins, postoperative vulvar radiotherapy may be considered to reduce the frequency of local recurrences. There is no consensus for the threshold of pathological margin distance below which adjuvant radiotherapy should be advised.
- B** Postoperative radiotherapy to the groin is recommended for cases with > 1 metastatic lymph node and/or presence of extracapsular lymph node involvement.
- ✓ Adjuvant radiotherapy for metastatic groin nodes should include the ipsilateral groin area and where pelvic nodes are non-suspicious on imaging, the distal part of the iliac nodes with an upper limit at the level of the bifurcation of the common iliac artery.
- C** Based on evidence from other squamous cell cancers such as cervical, head & neck, and anal cancer, the addition of concomitant, radiosensitising chemotherapy to adjuvant radiotherapy should be considered.

5.7 Chemoradiation

- C** Definitive chemoradiation with radiation dose escalation is the treatment of choice in patients with unresectable disease.
- C** In advanced stage disease neoadjuvant chemoradiation should be considered in order to avoid exenterative surgery.
- C** Radiosensitising chemotherapy, preferably with weekly cisplatin, is recommended.

5.8 Systemic treatment

- D** Data in vulvar cancer are insufficient to recommend a preferred schedule in a palliative setting.

5.9 Treatment of recurrent disease

Treatment of vulvar recurrence

- ✓ Radical local excision is recommended.
- ✓ For vulvar recurrence with a depth of invasion > 1 mm and previous sentinel lymph node removal only, inguinofemoral lymphadenectomy should be performed.
- ✓ The indications for postoperative radiotherapy are comparable to those for the treatment of primary disease.

Treatment of groin recurrence

- ✓ Restaging by CT or PET -CT of the thorax/abdomen/pelvis is recommended.
- ✓ Preferred treatment is radical excision when possible, followed by postoperative radiation in radiotherapy naïve patients.
- ✓ Based on evidence from other squamous cell cancers such as cervical and anal cancer, the addition of radiosensitising chemotherapy to postoperative radiotherapy should be considered.
- ✓ Definitive chemoradiation when surgical treatment is not possible.

Treatment of distant metastases

- ✓ Systemic palliative therapy may be considered in individual patients (see systemic treatment).

5.10 Follow-up



The optimal follow-up schedule for vulvar cancer is undetermined.



After primary surgical treatment the following follow-up schedule is suggested:

- First follow-up 6-8 weeks postoperative
- First two years every three-four months
- Third and fourth year biannually
- Afterward, long-term follow-up, especially in case of predisposing vulvar disease.

Follow-up after surgical treatment should include clinical examination of vulva and groins.²



After definitive chemoradiation the following follow-up schedule is suggested:

- First follow-up visit 10-12 weeks post completion of definitive chemoradiation.
- First two years every three-four months
- Third and fourth year biannually
- Afterward, long-term follow-up, especially in case of predisposing vulvar disease.

At first follow-up visit 10-12 weeks post definitive chemoradiation CT or PET -CT is recommended to document complete remission.

² Despite the well-recognized low sensitivity of palpation to identify groin recurrences, currently available data do not support routine use of imaging of the groins in follow-up.

6 Diagnosis and referral

6.1 Summary of available scientific evidence

No directly applicable clinical studies have been identified.

6.2 Previous initiatives

Four previous¹⁻⁴ initiatives presenting guidelines on diagnosis and referral were identified.

6.3 Development group comments

For accurate treatment planning (sentinel lymph node SLN) procedure: yes/no; expected uni-or bilateral lymph drainage; visibility of scar; etc. the localization of the primary tumour is important. Therefore excision biopsy should be avoided.

In case of multifocal macroinvasive vulvar cancer, the patient is not eligible for SLN detection, and inguinofemoral lymphadenectomy should be performed.

Because vulvar cancer is a rare disease and outcome of e.g. the SLN procedure is related to experience of the treating physician, treatment should be centralized in centres with adequate experience in the treatment of this disease.

6.4 Guidelines



In any patient suspected for vulvar cancer, diagnosis should be established by a punch/incision biopsy. Excision biopsy should be avoided for initial diagnosis, as this may obstruct further treatment planning.



In patients with multiple vulvar lesions, all lesions should be biopsied separately with clear documentation of mapping.



All patients with vulvar cancer should be referred to a GOC and treated by a multidisciplinary gynaecological oncology team.

7 Staging system

The TNM classification⁵ and the FIGO staging system^{6,7} classify vulvar cancer on the basis of the size of the tumour T, whether the cancer has spread to lymph nodes N), and whether it has spread to distant sites M

Table 1. By convention, the depth of invasion is defined from the epithelial-stromal junction of the most superficial adjacent dermal papilla to the deepest point of invasion of the tumour⁸. Inguinal and femoral nodes are the initial sites of regional spread and involvement of pelvic lymph nodes is considered distant metastasis.

The FIGO staging system was last reviewed in 2009 by the FIGO Committee on gynecologic oncology^{6,7} in close collaboration with the American joint commission on cancer and the Union of international cancer control. It should be noted that as part of this revised FIGO staging system, the pathologist must report not only the number of nodes with metastatic disease but also the size of the metastases and the presence or absence of extranodal spread.

7.1 Summary of available scientific evidence

No studies assessing the performance of the TNM classification have been identified.

Three retrospective studies⁹⁻¹¹ assessing the performance of the revised FIGO staging system have been identified. The new staging system has generally been considered appropriate. This has seen a major downstaging of between 18.3% to 42% of patients. This has mainly involved old patients with stage II disease being downstaged to stage IB. Among the 1,131 patients enrolled in these studies, only 6 patients were upstaged by the new system < 1%. Nevertheless, Tabbaa *et al.*¹⁰ suggested that tumours > 4 cm in diameter had a less favourable prognosis. A potential limitation with the revised FIGO staging system is that the number of patients with stage II disease will be very low. From the three retrospective studies above⁹⁻¹¹, about 20% of patients were classified as stage II in the old FIGO staging system, whereas it is likely to be less than 5% in the revised system.

LoE 2-

7.2 Previous initiatives

No previous initiative presenting guidelines on the staging system to use was identified.

7.3 Development group comments

The development group recommends using the TNM classification because it more accurately reflects the status of the primary tumour and lymph nodes.

7.4 Guidelines



Vulvar cancer should be staged according to FIGO and/or TNM classification³.

³ Throughout these recommendations advanced stage of disease is defined as clinical T3 and/or N3.

Table 1. Staging systems of squamous cell vulvar cancer

PRIMARY TUMOUR T		
TNM categories ⁵	FIGO stages ⁶	Definition
TX		Primary tumour cannot be assessed
T0		No evidence of primary tumour
Tis*		Carcinoma in situ
T1a	IA	Lesions ≤ 2 cm in size, confined to the vulva or perineum and with stromal invasion ≤ 1.0 mm**, no nodal metastasis
T1b	IB	Lesions > 2 cm in size or with stromal invasion > 1.0 mm*, confined to the vulva or perineum, with negative nodes
T2***	II	Tumour of any size with extension to adjacent perineal structures 1/3 lower urethra, 1/3 lower vagina, anus with negative nodes
T3****	IVA	Tumour invades upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or fixed to pelvic bone
REGIONAL LYMPH NODES N		
TNM categories ⁵	FIGO stages ⁶	Definition
NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N1		One or two regional lymph nodes with the following features
N1a	IIIA	One or two node metastasises, each 5 mm or less
N1b	IIIA	One lymph node metastasis 5 mm or greater
N2	IIIB	Regional lymph node metastasis with the following features
N2a	IIIB	Three or more lymph node metastases each less than 5 mm
N2b	IIIB	Two or more lymph node metastases 5 mm or greater
N2c	IIIC	Lymph node metastasis with extracapsular spread
N3	IVA	Fixed or ulcerated regional lymph nodes
DISTANT METASTASIS M		
TNM categories ⁵	FIGO stages ⁶	Definition
M0		No distant metastasis
M1	IVB	Distant metastasis including pelvic lymph node metastasis
<p>* FIGO no longer includes stage 0 Tis, ** the depth of invasion is defined as the measurement of the tumour from the epithelial-stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion, *** FIGO uses the classification T2/T3. This is defined as T2 in TNM, **** FIGO uses the classification T4. This is defined as T3 in TNM.</p>		

8 Preoperative investigations

8.1 Summary of available scientific evidence

Pathology review: two studies enrolling at least 50 pathology reports of vulvar tissues were identified. As part of a retrospective pathology report review, Beugeling *et al.*¹² assessed 1 the impact of pathology review on patient management and 2 the adequacy of the pathology reports, with regard to tumour type, infiltration depth, and, for excision biopsies, resection margins on 121 pathology reports from 112 patients. Two discrepancies have been reported 1.7% but the huge majority of reviewed reports showed no discrepancy 98.3%. In this study, a report stating histological type and depth of infiltration was considered “adequate”. Using this criterion, 56% of the original reports and 83% of the review reports were adequate. In the second identified study¹³, 113 pathology reports were reviewed and 4 major discrepancies were reported.

LoE 2+

Results from the 4 other identified studies¹⁴⁻¹⁷ are limited by the small number of pathology reports taken into account. These studies show a rate between 0% and 15.8% for major discrepancy **Table 2**. Among the 6 identified studies, it was not possible to estimate how many histology reviews would be necessary to find one major discrepancy. Half of the authors from the 6 identified studies^{12,15,16} have expressed doubt concerning the necessity of pathology report review for vulvar cancer.

Accuracy of clinical palpation to assess the lymph nodes status: four studies¹⁸⁻²¹ assessing the value of clinical palpation of the groin lymph nodes were identified. But only two studies^{18,21} have accrued in excess of 50 patients:

LoE 2+

- In a series of 258 patients treated with radical vulvectomy and bilateral groin lymphadenectomy, Iversen *et al.*¹⁸ reported metastases to the superficial and/or deep inguinal lymph nodes in 100 cases. Only 64 of which were detected by clinical examination. A false positive rate of 15.5% among the patients with clinically suspicious groin lymph nodes has been reported.
- Podratz *et al.*²¹ reported that the preoperative clinical staging efforts were incorrect in 25% of the cases 56/224 .

Among the 50 patients enrolled in the study published by Piura *et al.*¹⁹, data with respect to both clinical palpation and histopathologic examination of groin lymph nodes were available in 20 of the 26 patients who had radical vulvectomy and groin lymph node dissection. Authors have noticed that clinical palpation was not very reliable in detecting groin lymph node metastases. Overdiagnosis and underdiagnosis were present in 55.5% and 27.3% of patients sensitivity: 57.1%, specificity: 61.5%.

Thirty-nine patients out of the 59 patients enrolled in the fourth identified study²⁰ had inguinofemoral lymphadenectomy and all except one had bilateral groin node excision. Clinical findings were compared with histology result to assess test accuracy for a total of 77 groin nodes. In this study published by Singh *et al.*²⁰, clinical examination has a sensitivity of 35% and specificity of 94.3%.

Accuracy of MRI to assess the lymph nodes status: as part of a systematic review, Selman *et al.*²² compared the accuracy of non-invasive tests to assess the groin node status. One prospective²³ and one retrospective²⁴ studies assessing the value of the MRI have been included in this review for a total of 60 patients. MRI has a pooled sensitivity and specificity of 86% 95% CI = 0.57 -0.98 and 87% 95% CI = 0.74 -0.95 respectively in predicting the groin node status.

LoE 1-

Three other original studies^{20,25,26} were identified but only one study²⁵ has accrued in excess of 50 patients. In a retrospective study published by Bipat *et al.*²⁵, 60 patients underwent MRI examination for preoperative evaluation of lymph nodes. MRI images were read independently and retrospectively by two radiologists, both unaware of physical examination and surgery findings. Both

LoE 2+

observers detected 12 of the 23 positive groin nodes sensitivity: 52%. Of the 96 negative nodes, 14 and 11 were scored as positive by the observers specificity: 85% and 89% respectively. Singh *et al.*²⁰ 39 patients, 77 groin nodes reported consistent results with those described by Selman *et al.*²². MRI correctly identified metastatic nodal disease in 18 of the 21 positive groins and among the 56 negative groin nodes, 46 nodes were correctly identified on MRI, leading to a sensitivity of 85.7% and a specificity of 82.1%.

It should be noted that the used MRI criterion for groin lymph node metastasis prediction varied between the studies short -axis diameter of the node^{24,25}, short axis/long axis ratio, contour, and signal intensity^{20,23}. Kataoka *et al.*²⁶ used several criteria for evaluation of lymph node metastases of 49 patients 36 primary and 13 recurrent). A short axis/long axis ratio ≥ 0.75 was described as the most relevant criterion for diagnosis of groin lymph node metastasis in groin-by-groin analysis sensitivity: 86.7% and specificity: 81.3%. The presence of necrosis within a lymph node showed the highest specificity 87.5%, but lower sensitivity 40.0%. Furthermore, MRI accurately classified 31 out of 36 primary cancers accuracy: 86%. The addition of contrast -enhanced MRI did not change the accuracy of the size category of primary cancers accuracy: 85%.

Accuracy of PET to assess the lymph nodes status: Selman *et al.*²² pooled results of two prospective studies^{27,28} to assess the value of PET in the determination of groin nodes status 75 patients. PET has a pooled sensitivity and specificity of 71% 95% CI = 50 -86 and 72% 95% CI = 59 -82 respectively.

LoE 1-

One small original study²⁹ was also identified 20 patients. Of the 12 positive nodes, 6 were scored as positive sensitivity: 50% and all the 8 negative nodes were correctly identified specificity: 100%.

LoE 3

Accuracy of Ultrasound to assess the lymph nodes status: four prospective studies³⁰⁻³³ assessing the value of ultrasound have been included in the systematic review published by Selman *et al.*²². However, a pooled analysis could not be performed due to the difference between studies in techniques used to discriminate positive and negative groin nodes. Combining the results of another study³⁴ identified and independently of the test parameters used for ultrasound, the results showed sensitivity and specificity ranging from 45% to 100% and from 58% to 96% respectively

LoE 2+

Table 3. Moskvic *et al.*³⁰ combined ultrasound with ultrasound-guided fine-needle aspiration cytology FNAC to improve accuracy. This combined technique could accurately predict nodal status in the majority of cases. Falsely negative cytology occurred when the metastatic focus was ≤ 3 mm two false -negative results out of 40 groins. Hall *et al.*³¹, who extended the study of Moskvic *et al.*³⁰ to 44 patients, reported that the combination of ultrasound and FNAC provides a sensitive and specific tool for preoperative assessment sensitivity = 93%, specificity = 100%.

Accuracy of CT to assess the lymph nodes status: no literature is available on the diagnostic value of CT for detection of inguinofemoral lymph node metastases in patients with vulvar cancer. The only experience with CT in patients with vulvar cancer is the measurement of the distance in centimetres between the skin and the underlying inguinofemoral lymph nodes for planning of groin radiation^{35,36}.

LoE 4

8.2 Previous initiatives

Seven previous initiatives^{1-4,37-39} presenting guidelines on preoperative investigations were identified.

8.3 Development group comments

Size of the lesion, distance to the midline and palpation of the lymph nodes all determine the choice for primary treatment. Involvement of clitoris, anus, and/or urethra often means that these structures will need to be radically excised together with the primary tumour. Such information is important for treatment planning and informing the patient. In case of clitoral/anal/urethral involvement, primary radiochemotherapy might be an alternative.


In patients with primary unifocal vulvar cancer <4 cm, inguinofemoral lymphadenectomy can be performed immediately instead of SLN procedure in case when lymph node metastases are diagnosed preoperatively. CT or PET/CT can be performed to rule out involvement of pelvic nodes and to decide whether or not to perform pelvic nodal debulking. Presence of distant metastases should also be evaluated as their presence or absence may influence the radicality of treatment of the primary tumour and the regional lymph nodes.

Treatment policy for melanomas and basal cell cancer for example is different. Depth of invasion is necessary to decide whether groin treatment is indicated, both in squamous cell cancers as well as in melanomas.

8.4 Guidelines



Preoperative work-up should at least include clear documentation of clinical exam size of lesion, distance to the midline/clitoris/anus/vagina/urethra and palpation of lymph nodes. Picture or clinical drawing is advised see below.



Evaluation of the cervix/vagina/anus is recommended.



Prior to sentinel lymph node biopsy, clinical examination and imaging of the groins either by ultrasound, PET-CT, or MRI are required to identify potential lymph node metastases.



Suspicious nodes at palpation and/or imaging should be analysed by FNA or core biopsy when this would alter primary treatment.



Further staging with CT thorax/abdomen and pelvis is recommended where there is a clinical suspicion of, or proven nodal) metastatic disease and/or advanced stage disease.



The pathology report on preoperative biopsy should at least include histological type and depth of invasion.

Table 2. Original studies presenting data on pathology slide review

Author ^{reference}	Year	N	Major discrepancy	Minor discrepancy
Beugeling <i>et al.</i> ¹²	2014	121	1.7% 2/121	0% 0/121)
Santoso <i>et al.</i> ¹³	1998	113	3.5% 4/113	10.6% 12/113)
Chafe <i>et al.</i> ¹⁴	2000	28	7.1% 2/28	32.1% 9/28
Khalifa <i>et al.</i> ¹⁵	2003	28	0% 0/28	10.7% 3/28
Selman <i>et al.</i> ¹⁶	1999	19	15.8% 3/19	0% 0/19
Chan <i>et al.</i> ¹⁷	1999	13	15.4% 2/13	15.4% 2/13

Table 3. Original studies presenting data on the accuracy of imaging to assess the groin node status

Author ^{reference}	Year	TP	FP	TN	FN	Sensitivity	Specificity
MRI							
Hawnaur <i>et al.</i> ^{23*}	2002	8	1	10	1	89%	91%
Sohaib <i>et al.</i> ^{24*}	2002	4	5	30	1	80%	56%
Bipat <i>et al.</i> ²⁵	2006						
observer 1		12	14	80	11	52%	85%
observer 2		12	11	90	11	52%	89%
Singh <i>et al.</i> ²⁰	2006	18	10	46	3	85.7%	82.1
Kataoka <i>et al.</i> ²⁶	2010						
short axis/long axis ratio ≥ 0.75)		26	3	13	4	86.7%	81.3%
contour		21	7	8	9	70.0%	53.3%
necrosis		12	2	14	18	40.0%	87.5%
loss of fatty hilum		24	8	8	6	80.0%	50.0%
similarity of signal intensity to vulva lesion)		23	8	3	3	88.5%	27.3%
PET							
Cohn <i>et al.</i> ^{27*}	2002	6	2	18	3	67%	90%
de Hullu <i>et al.</i> ^{28*}	1999	9	13	21	3	75%	62%
Kamran <i>et al.</i> ²⁹	2014	6	0	8	6	50%	100%
Ultrasound							
de Gregorio <i>et al.</i> ³⁴	2013	29	6	63	9	76%	91%
Hall <i>et al.</i> ^{31*}	2003	24	2	43	4	86%	96%
Makela <i>et al.</i> ^{32*}	1993	9	5	34	2	81%	87%
Moskovic <i>et al.</i> ^{30*}	1999	11	5	25	2	85%	83%
Abang Mohammed <i>et al.</i> ^{33*}	2000						
short axis		5	3	28	6	45%	90%
long/shot axis ratio)		6	10	14	0	100%	58%
combined)		5	3	21	1	83%	87%

* studies included in the systematic review published by Selman *et al.*²², FN: false negative, FP false positive, TN: true negative, TP: true positive.

9 Surgical management

9.1 Summary of available scientific evidence

Radical/wide local excision versus radical vulvectomy: none of the five identified studies⁴⁰⁻⁴⁴ reported statistically significant differences in overall survival, disease-free survival, local or distant recurrence rates between patients treated by radical/wide local excision and patients treated by radical vulvectomy:

LoE 2+

- In a retrospective study enrolling 74 patients T1 -2N0-1M0, Farias -Eisner *et al.*⁴⁰ compared the effectiveness and safety of a radical local excision N = 56 versus radical vulvectomy N = 18. Of women with stage I disease, the 5-year survival was similar for those patients who underwent the more conservative operation 97% compared with those who underwent a radical vulvectomy 100%. The difference in the overall survival of stage II patients undergoing radical local excision versus radical vulvectomy did not reach statistical significance 90% versus 75%, $p > 0.05$. Operative morbidity was less in those undergoing a conservative operation. Serious infection, necrosis, or major breakdown of the primary wound occurred in 21% and 14% patients undergoing radical local excision and radical vulvectomy, respectively.
- Similar overall survival, local control and 5-year disease-free survival rates were reported by Balat *et al.*⁴¹ between 25 patients treated by wide local excision and 24 patients treated by radical vulvectomy 73% versus 67%, 83% versus 80%, and 75% versus 67%, respectively. In this retrospective study, all patients received irradiation combined with surgery. There were fewer complications eg lymphedema, wound infection, lymphocyst, vulvar dystrophy in the patients treated by wide local excision than in those treated with radical vulvectomy. Similar local recurrence rates were reported by de Hullu *et al.*⁴² between patients treated by wide local excision and patients treated by radical vulvectomy 11.4% 9/79 versus 7.5% 12/159, $p = 0.32$. An analysis of the exact tumour free margins among 39 patients treated by wide local excision showed that no patient with histologic tumour free margins measuring > 8 mm developed a local recurrence, whereas 9 of 40 patients with at least one tumour free margin measuring ≤ 8 mm developed local recurrences within 2 years $p = 0.002$. As Balat *et al.*⁴¹, there was no difference in overall survival between two groups of patients. Rutledge *et al.*⁴³ undertook an analysis of 179 stage I and II lesions treated with a curative aim to see if there was a difference in survival or in disease-free interval between those patients treated with radical vulvectomy and those treated with radical wide local excision. No survival advantage from the radical vulvectomy procedure has been reported data not shown.
- No statistical correlation between the type of primary surgery performed and the frequency of recurrence to any site were described by DeSimone *et al.*⁴⁴ in a retrospective study enrolling 122 patients with lateral T1 N = 61 and T2 N = 61 vulvar cancer confined to the labium majus and labium minus local: 13% versus 8%, $p = 0.33$, groin: 0% versus 3%, $p = 0.50$, distant pulmonary: 2% versus 3%, $p = 1.0$, total: 15% versus 15%, $p = 1.0$. It should be noted that lymphoedema occurred more commonly in patients undergoing radical vulvectomy than in patients undergoing radical wide excision 26% versus 7.5%, $p = 0.007$. Likewise, both wound separation 23% versus 7.5% and lymphocyst formation 6.7% versus 3.2% were more common in patients undergoing radical vulvectomy.

As part of Cochrane systematic review, van der Velden⁴⁵ also assessed the effectiveness and safety of a radical local excision. Two observational studies^{46,47} enrolling 94 patients TINOM0: N = 51, T2NOM0: N = 43 have been included in this systematic review. No pooled analysis is described and it should be noted that details regarding radiotherapy interventions were not addressed and the grade of complications was not defined in any study. Furthermore, an adequate description of common complications was not stated in one study⁴⁷. Authors reported a recurrence rate of 0%⁴⁷ and 12%⁴⁶.

LoE 2-

None of the patients with a local recurrence died of vulvar cancer after a median follow-up of 38 months.

Three other studies⁴⁸⁻⁵⁰ documenting recurrence rates after radical/wide local excision were identified 0%⁴⁸ 0/18 patients with stage I, 23.1%⁴⁹ 28/121 patients with stage I and II, and 10%⁵⁰ 5/50 patients with stage I.

LoE 2+

Only one study comparing quality of life of patients treated by wide local excision versus radical vulvectomy was identified. In this retrospective 57 patients, Gunther *et al.*⁵¹ observed tendencies for a better physical, role, emotional, and cognitive functioning, as well as global health status after surgical treatment with wide local excision. Patients who underwent radical vulvectomy suffered from a significant higher level of pain than those who underwent wide local excision. In addition, these patients suffered from nausea/vomiting, fatigue, insomnia, appetite loss, and diarrhoea to a higher degree $p > 0.05$. It should be noted that after radical vulvectomy, 89% of patients have sexual complications.

Omission of Inguinofemoral lymphadenectomy: the presence of pelvic node metastases is very rare in the absence of inguinofemoral lymph node metastases. Thirty percent of all patients with vulvar cancer have inguinofemoral metastases and 20% of these patients will have pelvic metastases, too^{52,53}. None of the seven identified studies^{49,54-59} described positive lymph nodes or inguinal recurrences after a minimal follow-up of two years in patients with very early stage vulvar cancer, where the primary lesion measures less than 2 cm in maximum diameter and the depth of invasion is less than 1 mm FIGO stage IA disease. Among the 30 patients who underwent surgery without lymphadenectomy in the study published by Magrina *et al.*⁵⁹, one developed groin, pelvic, and aortic node metastases 7.5 years after initial operation and 3.5 years after experiencing a vulvar recurrence the primary lesion measured 2 x 1.5 cm, was moderately well differentiated, and was located to the left of the clitoris with only 0.1 mm of invasion. In contrast, with infiltration of 1 -2 mm, lymph node metastases or inguinal recurrences were seen from 0 to 17%⁵⁴⁻⁵⁷.

LoE 2+

Several case reports⁶⁰⁻⁶⁵ of regional lymph node recurrences following treatment for FIGO stage IA vulvar cancer have been published but no pattern of particular risk factors can be defined from this small number of cases.

LoE 3

Superficial inguinal lymphadenectomy versus total inguinofemoral lymphadenectomy: as part of a retrospective study enrolling 217 patients with stage I disease 5 mm or less invasion, no vascular space involvement, and negative inguinal and femoral nodes, Stehman *et al.*⁶⁶ reported a groin recurrence in 7.3% of patients treated with superficial inguinofemoral lymphadenectomy versus 0% recurrences in those treated with radical vulvectomy and bilateral inguinofemoral lymphadenectomy historic controls. The recurrent -free interval was significantly lower for patients treated with superficial inguinal lymphadenectomy compared to historic controls 84.2% 102/121 versus 91.8% 9 0/98, $p = 0.0028$. For survival time, the difference did not reach statistical significance 87.6% 106/121 versus 82.6% 81/98, $p > 0.05$.

LoE 2-

Three uncontrolled studies^{50,67,68} evaluating outcomes of patients treated with superficial inguinal lymphadenectomy were also identified. Among the 104 patients stage I or II, depth of invasion greater than 1 mm treated with radical wide excision negative margins and superficial inguinal lymphadenectomy, Gordinier *et al.*⁶⁷ reported that nine patients experienced recurrent disease that involved one or both of the groins 8.6%. Berman *et al.*⁵⁰ reported outcomes of 50 patients with T1 vulvar cancers < 1 cm diameter with stromal invasion > 5 mm who underwent radical wide excision and superficial inguinal lymphadenectomy. There were no isolated groin recurrences noted during a follow-up period of 36 months. The third study⁶⁸ reported that three of the 65 patients with stage I/II vulvar cancer and a pathologically negative superficial inguinal lymphadenectomy recurred in the inguinal region 4.6%.

LoE 2+

Unilateral inguinofemoral lymphadenectomy versus bilateral inguinofemoral lymphadenectomy: the risk of recurrent disease in a contralateral groin after ipsilateral groin node dissection in patients with T1 or T2 lesions confined to the labium majus or minus is very low. Among the five identified studies^{44,46,66,69,70} for a total of 295 patients, only four recurrent diseases in a contralateral groin after ipsilateral groin node dissection have been reported 1.4%. **LoE 2+**

A case report⁷¹ of a contralateral recurrence 2.5 years after wide local excision and unilateral groin node dissection in a patient with a T1 lesion without clinically palpable groin nodes has been also identified. **LoE 3**

As part of a thesis, van der Velden⁷² found that 19 out of 489 patients 3.9% with unilateral vulvar tumours and negative ipsilateral lymph nodes had positive contralateral lymph nodes. In a subgroup analysis taking into account patients with tumours < 2 cm, the incidence of contralateral lymph nodes is only 0.9%. **LoE 2+**

Preservation of the saphenous vein: among the seven identified studies⁷³⁻⁷⁹, Zhang *et al.*⁷³ showed that preservation of the saphenous vein was associated with a statistically significant decrease in the occurrence of cellulitis, short-term lower extremity lymphoedema, wound breakdown, and chronic edema 18% versus 39%, $p = 0.006$, 32% versus 70%, $p < 0.001$, 13% versus 38%, $p = 0.001$, 32% versus 3%, $p = 0.003$, respectively compared to saphenous vein ligation without compromising the local or distant recurrent disease rates data not shown. Overall, the likelihood of developing no postoperative complications was higher in the saphenous vein preservation group compared with the saphenous vein ligation group 56% versus 23%, $p < 0.001$. **LoE 2+**

More recently, Zhang *et al.*⁷⁴ reported that preservation of the saphenous vein was associated with a statistically significant decrease by about 50% in the occurrence of chronic lower limb lymphoedema, chronic lower extremity pain, chronic cellulitis, and sensory abnormalities 25.0% versus 48.3%, $p < 0.01$, 23.2% versus 46.6%, $p < 0.01$, 21.4% versus 41.4%, $p < 0.05$, and 19.6% versus 36.2%, $p < 0.05$ respectively without compromising 5-year survival rate and groin recurrence rate 68% versus 66.7%, $p > 0.05$ and 8.9% versus 12.1%, $p > 0.05$, respectively. Short-term lower extremity lymphoedema and short-term lower extremity phlebitis were also less frequent in patients treated by saphenous vein sparing surgery to those treated by lymphadenectomy with saphenous vein ligation 43.5 versus 66.7%, $p < 0.01$, and 11.3% versus 25.8%, $p < 0.05$, respectively.

Similarly, Rouzier *et al.*⁷⁵ reported that lymphadenectomy with saphenous vein preservation is associated with a significant decrease in the occurrence of wound breakdown, cellulitis and lymphoedema compared to lymphadenectomy with saphenous vein ligation 16.2% versus 36.4%, $p < 0.001$, 17.7% versus 29.8%, $p = 0.01$, and 23.1% versus 45.3%, $p < 0.001$, respectively. A significant differences in the occurrence of cellulitis and wound breakdown were also described by Dardarian *et al.*⁷⁶ in favour of saphenous vein sparing surgery 0% versus 45%, $p < 0.001$, and 0% versus 25%, $p \leq 0.02$, respectively. Subsequently, chronic lymphoedema > 6 months persisted in 38% of the vein-ligated group compared to 11% in the vein-spared group $p < 0.05$ without compromising the incidence of recurrent disease 19.3% versus 22.2%, $p > 0.05$ ⁷⁶.

However, preservation of the saphenous vein was not systematically associated with a statistically significant decrease of morbidity. Zhang *et al.*⁷³ observed that the difference of seroma, phlebitis, deep vein thrombosis, and hematoma in favour of saphenous vein sparing surgery did not reach statistical significance 3% versus 8%, $p = 0.29$, 0% versus 3%, $p = 0.50$, 2% versus 5%, $p = 0.38$, 0% versus 3%, $p = 0.50$, respectively. More recently, Zhang *et al.*⁷⁴ observed also that the difference of acute cellulitis, seroma, lymphocyst formation, chronic lower extremity phlebitis, and deep venous thrombosis with saphenous vein sparing surgery did not reach statistical significance 67.7% versus 72.7%, $p > 0.05$, 30.6% versus 37.9%, $p > 0.05$, 25.8% versus 31.8%, $p > 0.05$, 10.7% versus

15.5%, $p > 0.05$, 7.1% versus 10.3%, $p > 0.05$, respectively. Dardarian *et al.*⁷⁶ showed that the difference of short-term oedema in favour of saphenous vein ligation did not reach statistical significance 67% versus 72%, $p > 0.05$. Finally, groin wound breakdown or cellulitis occurred in 18% of patients with saphenous vein preservation, and 24% where the vein was sacrificed in the study published by Paley *et al.*⁷⁷.

In contrast, some investigators^{73,74,77,78} described an increase of morbidity in patients with saphenous vein sparing compared to patients where it was sacrificed. Paley *et al.*⁷⁷ described an increase of the incidence of lymphoedema and lymphocyst formation 36% versus 21%, 27% versus 14%, respectively. Zhang *et al.*^{73,74} observed a slight increase of postoperative fever, lymphocyst formation, and pulmonary embolism 96.8% versus 93.9%, 10% versus 4%, 2% versus 0%, respectively but it should be noted that the differences did not reach statistical significance $p > 0.05$, $p = 0.19$, $p = 0.45$, respectively. In the study published by Lin *et al.*⁷⁸, lymphoedema occurred in 17% of patients who had preservation of the long saphenous vein during the groin dissection versus 13% in whom the long saphenous vein was sacrificed $p = 0.50$. It should be noted that the risk of groin recurrence did not change with preservation of the saphenous vein 6% versus 6%.

Finally, Soliman *et al.*⁷⁹ did not find significant correlations between saphenous vein ligation and the development of any local complications data not shown.

Triple incision technique versus en bloc dissection the butterfly incision : no randomised trials have been performed to evaluate whether the use of the triple incision technique is as safe as the *en bloc* approach, but all the identified studies^{42,80-83} that compared these two surgical approaches showed that vulvectomy and inguinofemoral lymphadenectomy via three separate incisions provide similar outcome in terms of survival compared to an *en bloc* butterfly resection. In multivariate analysis, van der Velden *et al.*⁸¹ reported that surgical technique has no impact on disease-specific survival after adjustment for tumour diameter, extracapsular lymph node involvement, TNM stage, and number of nodal metastases, HR = 0.99, 95% CI = 0.43-2.30, $p = 0.996$ and overall survival data not shown. After correction for tumour dimension, depth of invasion, presence or absence of lymph/vascular invasion, and grade, de Hullu *et al.*⁴² observed that wide local excision with inguinofemoral lymphadenectomy through separate incisions was not related independently to an increased risk of death within 4 years related to vulvar carcinoma OR = 1.98, 95% CI = 0.80 -4.80, $p > 0.05$ even if they described more frequent fatal recurrences in the groin or the skin bridge 6.3% versus 1.3%, $p = 0.029$.

LoE 2+

Among the seven identified studies^{42,80-85}, a skin bridge recurrence was observed in only 1.8% of patients 6/336. It should be noted that Hacker *et al.*⁸⁴ published 2 skin bridge recurrences, both in patients with lymph node metastases. However, the majority of identified studies^{42,81,83} described a lower local recurrence rate among patients treated by an *en bloc* resection. With regard to the risk of vulvar recurrence, van der Velden *et al.*⁸¹ reported that patients treated by an *en bloc* resection showed a significantly lower risk of local recurrence than those treated by the triple incision technique after adjustment for tumour diameter, extracapsular lymph node involvement, TNM stage, and number of nodal metastases HR = 0.10, 95% CI = 0.02 -0.44, $p = 0.002$. But the type of surgical treatment was not an independent predictor for regional recurrence HR = 0.39, 95% CI = 0.13-1.17, $p > 0.05$ or distant recurrence HR = 0.97, 95% CI = 0.32 -2.91, $p > 0.05$. In multivariate analyses, after correction for tumour dimension, depth of invasion, presence or absence of lymph/vascular invasion, and grade, de Hullu *et al.*⁴² mentioned that wide local excision with inguinofemoral lymphadenectomy through separate incisions was associated with a higher risk of developing recurrences 2 and 4 years after primary treatment OR = 2.29, 95% CI = 1.00 -5.28, $p < 0.05$, and OR = 2.272, 95% CI = 1.11-4.67, $p < 0.05$, respectively.

LoE 2+

Fambrini *et al.*⁸⁶ assessed the feasibility and safety of a modified triple incision total radical vulvectomy and inguinofemoral lymphadenectomy in 57 patients with locally advanced vulvar

cancer LAVC. In all cases, two teams performed the surgery: one for total radical vulvectomy and the other for inguinofemoral lymphadenectomy. Surgical procedures started at the same time and were performed according to standard triple incision technique. Postoperative complications involving the surgical sites or lymphatic drainage were observed in one third of patients 19/57. None of them required surgical re-intervention. After treatment 29 patients developed local, regional or distant recurrence of disease, with a median progression-free survival of 39.5 ± 20.9 months. Three-year and 5-year overall survival OS were of 60.5% and 48.6%, respectively.

9.2 Previous initiatives

Nine previous initiatives^{1-4,37-39,87,88} presenting guidelines surgical management were identified.

9.3 Development group comments

Vulvectomy in addition to radical local excision can be considered in tumours with extensive premalignant disease to reduce the risk of local recurrence. Data on surgical margins are conflicting. Therefore, the development group advises to consider narrow margins when this means clitoris/anus can be preserved.

Treatment of advanced stage vulvar cancer often involves multiple treatment modalities. Treatment planning is often individualized in advanced stage and depends on primary tumour characteristics and presence of regional and/or distant metastases. Also comorbidity and/or frailty of the patient influences treatment planning. Therefore, a multidisciplinary setting is needed to optimize treatment planning.

In case of enlarged groin nodes either inguinofemoral lymphadenectomy followed by radiotherapy, or groin node debulking followed by radiotherapy can be considered. When imaging shows enlarged pelvic nodes, debulking of these nodes is recommended with adjuvant radiotherapy, since radiotherapy alone will probably not sterilize large nodal pelvic disease.

9.4 Guidelines

Local treatment

- C** Radical local excision is recommended.
- ✓ Consider additional, more superficial resection of d-VIN in addition to radical local excision of invasive tumours.
- ✓ In multifocal invasive disease radical excision of each lesion as a separate entity may be considered. Vulvectomy may be required in cases with multifocal invasion arising on a background of extensive vulvar dermatosis.
- ✓ The goal of excision is to obtain tumour-free pathological margins. Surgical excision margins of at least 1 cm are advised. It is acceptable to consider less wide margins where the tumour lies close to midline structures clitoris, urethra, anus and preservation of their function is desired.
- ✓ When invasive disease extends to the pathological excision margins of the primary tumour, reexcision is treatment of choice.
- ✓ Advanced stage patients should be evaluated in a multidisciplinary setting to determine the optimal choice and order of treatment modalities.

Groin treatment

- C** Groin treatment should be performed for tumours > pT1a.
- B** For unifocal tumours < 4 cm without suspicious groin nodes on clinical examination and imaging any modality the sentinel lymph node procedure is recommended.
- C** For tumours ≥ 4 cm and/or in case of multifocal invasive disease inguinofemoral lymphadenectomy by separate incisions is recommended. In lateral tumours medial border > 1 cm from midline ipsilateral inguinofemoral lymphadenectomy is recommended. Contralateral inguinofemoral lymphadenectomy may be performed when ipsilateral nodes show metastatic disease.
- D** When lymphadenectomy is indicated, superficial and deep femoral nodes should be removed.
- C** Preservation of the saphenous vein is recommended.
- ✓ The optimal management of the groin full inguinofemoral lymphadenectomy or isolated removal only for enlarged, proven metastatic nodes remains to be defined.
- ✓ Where enlarged > 2 cm pelvic nodes are identified, their removal should be considered.

Reconstructive surgery

- ✓ Availability of reconstructive surgical skills as part of the multidisciplinary team is required in early as well as advanced stage disease.

10 Sentinel lymph node procedure

10.1 Summary of available scientific evidence

Diagnostic test accuracy according to the mapping method: three meta-analyses⁸⁹⁻⁹¹ assessing the diagnostic accuracy of SLN biopsy were identified. Hassanzade *et al.*⁸⁹, Meads *et al.*⁹⁰, and Lawrie *et al.*⁹¹ included 47 studies⁹²⁻¹³⁸, 29 studies^{97,98,109,110,113-120,124-126,129,135,136,139-148}, and 34 studies^{92,93,95,97-99,103,104,107,109,110,112,114-119,122-127,129,135,136,140-144,149-169}, respectively. It should be noted that studies included in these meta-analyses had methodological limitations, such as lack of an adequate description of population especially stage of disease, inclusion criteria, assessment procedure, and reference standard used. Data from different reports of the same study were also taken into account.

LoE 1-

Two meta-analyses^{89,90} reported pooled patient basis detection rate of various techniques and provided evidence that a combination of blue dye/99mTc is the most accurate technique **Table 4**. It should be noted that many of the studies taken into account by Meads *et al.*⁹⁰ were also included in the pooled analysis performed by Hassanzade *et al.*⁸⁹, which explains the consistency of results. Only Hassanzade *et al.*⁸⁹ published pooled groin basis detection rate data and observed that it was also higher with the use of the combined blue dye and 99mTc testing **Table 4**.

Two of the three identified meta-analyses^{89,91} described per patient and per groin pooled sensitivity of the SLN biopsy and provide evidence that a combination of blue dye/99mTc is also the most sensitive technique **Table 4**. It should be noted that many of the studies taken into account by Lawrie *et al.*⁹¹ were also included in the pooled analysis performed by Hassanzade *et al.*⁸⁹, which explains the consistency of results.

Diagnostic test accuracy according to the location of the tumour: Hassanzade *et al.*⁸⁹ reported that diagnostic test accuracy of the SLN procedure is also related to location of the tumour. For midline lesions ≤ 2 cm of midline, per groin pooled detection rate was 22% lower than per patient pooled detection rate but groin basis pooled sensitivity was 4% higher than patient basis pooled sensitivity **Table 5**. However, for lateral lesions > 2 cm from the midline plane, per patient and per groin pooled detection rates and sensitivity were similar.

LoE 1-

Diagnostic test accuracy according to the tumour size: Hassanzade *et al.*⁸⁹ observed that pooled patient basis sensitivity was also related to the size of the primary tumour. Indeed, the pooled sensitivity of SLN mapping in < 4 cm tumours was 7% higher than > 4 cm tumours < 4 cm: 93% 95 % CI = 87-97, > 4 cm: 86% 95% CI = 77 -93. It should be noted that, in the Groningen international study on sentinel nodes in vulvar cancer GROINSS -V)¹⁷⁰, sentinel-node detection was done in patients with T1-T2 < 4 cm squamous -cell vulvar cancer.

LoE 1-

Diagnostic test accuracy according to the inclusion of patients with palpable or suspicious inguinal nodes in the study population: Hassanzade *et al.*⁸⁹ observed that per patient and per groin pooled patient basis detection rate and sensitivity were lower among patients with palpable or suspicious inguinal nodes **Table 5**.

LoE 1-

Diagnostic accuracy of intraoperative pathologic analysis of frozen sections: as part of the GROINSS-V)¹⁷⁰, frozen sectioning was done in 315 and showed a low sensitivity 48% but a high specificity 100%.

LoE 2++

In contrast, two older and smaller studies 52 patients¹⁴² and 42 patients¹⁴¹ found sensitivity greater than 90%. It should be noted that these two studies^{141,142} reported a specificity for intraoperative analysis of SLN by frozen section greater than 90%. In the fourth identified study¹¹⁵, 18 positive nodes were detected in 13 of the 43 enrolled women 30.2%. In two cases, although the frozen section was negative, the definitive histopathologic examination revealed a micrometastasis

LoE 2+

accuracy: 98%.

Diagnostic test accuracy according to histological methods: only one of the three identified meta-analyses⁹¹ described pooled estimates of sensitivity for the combined technique blue dye/99mTc according to histological methods:

- Ultrastaging only: 95% 95% CI = 91 -97 per groin data, 95% 95% CI = 89 -98 per patient data
- Ultrastaging and/or immunohistochemistry IHC: 94% 95% CI = 88 -97 per groin data, 95% 95% CI = 90 -98 per patient data

LoE 1-

In the GROINSS-V¹⁷⁰, ultrastaging detected a positive SLN in 55 41% of 135 patients 66 40% of 164 groins. After multiple sectioning, IHC identified micrometastases in 36 12% of 304 patients with a negative sentinel node. The risk of metastases in non-SLN was higher when the SLN was found to be positive by traditional pathologic processing than when the SLN was found to be positive only with ultrastaging 23 of 85 groins 27% versus 3 of 56 groins 5%, $p = 0.001$. In Gynecologic oncology group GOG) protocol 173¹³⁵, 23% of all positive SLNs were missed by routine H&E staining of SLN tissue cut and were only detected with the addition of immunohistochemical stains.

LoE 2++

Nine smaller studies^{50,54,58,65,67,77,84,112,118} have also reported micrometastases found after ultrastaging and/or IHC among patients that were previously negative with standard H&E.

LoE 2+

Visualization of the SLN by scintigraphy: in GOG protocol 173, Coleman *et al.*¹⁵⁵ reported a negative correlation between distance of vulvar lesion from midline and the probability of detecting bilateral drainage in preoperative lymphoscintigraphy. Thirty percent of women with tumours invading or crossing the midline had unilateral drainage on lymphoscintigraphy. However, authors observed that more than one in five patients with lateralized primary tumours > 2 cm from the midline had bilateral drainage on lymphoscintigraphy.

LoE 2++

Out of 42 patients with midline tumours enrolled in the retrospective review published by Lindell *et al.*¹²⁵, only 18 had bilateral lymphatic drainage at scintigram. The lymphoscintigraphy showed unilateral lymphatic drainage in 40 out of 58 patients, including all 16 patients with lateral lesions. Louis-Sylvestre *et al.*¹⁵⁷ found that of 13 patients with lesions less than 1 cm from the midline in whom lymphoscintigraphy identified only unilateral drainage, 3 patients had metastatic disease in nodes located in the contralateral, lymphoscintigraphy-negative groin. Six identified studies^{102,117,118,160,171,172} assessed detection rate of the preoperative visualization of the SLN by scintigraphy and all of them reported a detection rate greater than 90%.

LoE 2+

De Cicco *et al.*⁹⁷ used preoperative and intraoperative lymphoscintigraphy alone to successfully identify at least one sentinel node in each of the 37 patients in their series. There were no false-negative sentinel nodes. Eight patients had positive nodes, and the sentinel node was the only positive node in 5 of these cases. If lymphoscintigraphy did not identify a sentinel node in a groin, no metastases were found at surgery. Using a combination of preoperative lymphoscintigraphy and intraoperative lymphoscintigraphy, de Hullu *et al.*⁹⁸ reported that all the 23 patients with lateral lesions or with tumours primarily labial but came within 1 cm of the midline had unilateral SLN detected in the groin on preoperative lymphoscintigraphy and at the time of surgery.

In a very small study enrolling 10 patients, DeCesare *et al.*⁹³ showed that intraoperative lymphoscintigraphy correctly identified the nodal status as positive in all 4 cases of metastatic disease and negative in all 16 groins negative for metastases.

Impact of training and experience of the surgeon on the diagnostic accuracy: Several authors^{118,120,145,173,174} have suggested surgeons should perform at least 10 successful SLN biopsy procedures followed by complete inguinofoveal lymph node dissection without any false-negative results prior to performing SLN biopsy alone. In order to keep the experience at a high level, van der Zee *et al.*¹⁴⁵ proposed that an exposure of at least five to 10 patients per year per surgeon should be regarded as a minimum figure, requiring potentially centralization of early-stage vulvar cancer treatment in oncology centres. **LoE 4**

As part of a prospective study enrolling 52 patients, Levenback *et al.*¹⁴² reported that the number of cases in which the sentinel node is not identified or in which there is a false-negative sentinel node decreases with experience. Indeed, a sentinel node could not be identified in 4 of the 25 16% patients and 13 of the 36 36% groins dissected, compared with 2 of the 27 7% of patients treated and 6 of the 40 15% groins dissected during the first two years of the study $p = 0.034$. **LoE 2+**

Recurrence and survival rates following SLN procedure: in the GROINSS-V¹⁷⁰, five-year disease-specific survival for patients with positive sentinel nodes was 64.9% when identified by routine pathology versus 92.1% when identified by ultrastaging $p < 0.0001$. The update of the GROINSS-V-I¹⁷⁵ 377 patients highlighted that on the long-term a significant proportion of patients will develop a local recurrence, regardless of sentinel node status and that these local recurrences may occur even a long time after primary treatment. This prospective study also showed that long-term survival is very good for patients with early-stage vulvar cancer and a negative sentinel node. After a median follow-up of 105 months, Te Grootenhuys *et al.*¹⁷⁵ reported an overall local recurrence rate of 24.6% at 5 years and 36.4% at 10 years for sentinel node negative patients, and 33.2% and 46.4% for sentinel node positive patients, respectively $p = 0.03$. Disease-specific 10-year survival was 91% for sentinel node negative patients compared to 65% for sentinel node positive patients $p < 0.0001$. Overall 5- and 10-year survival was also better for sentinel node negative patients 5y -OS: 81.2% versus 61.3%, 10y-OS: 68.6% versus 43.6%, $p < 0.0001$. **LoE 2++**

As part of a health technology assessment comparing SLN biopsy and inguinal lymph node dissection (ILND), Reade *et al.*¹⁷⁶ reported from 11 studies^{93,96,113,114,117,132,145-147,177,178} enrolling 591 patients a groin recurrence rate after a negative SLN biopsy of 3.6% range 0 to 22%. It should be noted that follow-up in these studies was variable, but in most was at least two years. A recurrence rate after ILND of 4.3% was also reported 13 studies^{46,66-68,179-187} enrolling 1,077 patients. It should be noted that, in general, there was longer follow-up in these studies than in the studies of SLN biopsy.

Multivariate analyses performed from the surveillance, epidemiology, and end results database on 1,094 patients¹⁸⁸ showed that SLN biopsy was not significantly associated with an excess risk of mortality or recurrence after adjustment for age, ethnicity, stage, grade, and lymph node status data not shown. **LoE 2-**

Complication rates & clinical parameters: Reade *et al.*¹⁷⁶ compared also complication rates between SLN biopsy 6 studies^{113,117,120,145,146,178}, 532 patients and ILND 27 studies^{46,66,68,73-76,78,82,85,117,120,145,178,179,182,183,186,189-197}, 2,135 patients. Wound infection, wound breakdown, lymphocysts, and chronic lymphoedema after SLN biopsy were 4.4%, 9.5%, 3.8%, and 1.5%, respectively. The rate of groin wound infection after ILND across all studies was 30.7%, groin wound breakdown occurred in 23.2%, and lymphocysts occurred in 15.5%. Chronic lymphoedema occurred in 22.9% across all studies. **LoE 2++**

In a retrospective study enrolling 128 patients, Brammen *et al.*¹⁷¹ reported also a higher presence of lymph cysts after ILND compared to SLN biopsy OR = 3.4 95% CI = 1.1 -10.6, $p = 0.02$. In addition, three original studies^{145,171,178} reported significantly higher operation time, hospital stay or duration of inguinal drainage after ILND **Table 6.** **LoE 2+**

Quality of life: one study¹⁹⁸ investigated quality of life in 62 patients who participated in the GROINSS-V study. Using the EORTC QLQ-C30 questionnaire, no difference in overall quality of life was observed between the 35 patients who underwent the SLN-procedure alone and the 27 patients who underwent an inguinofemoral lymphadenectomy. The major difference was the increase in complaints of lymphoedema of the legs after inguinofemoral lymphadenectomy $p = 0.01$. Patients who underwent inguinofemoral lymphadenectomy also reported more discomfort in groins, vulva and legs $p = 0.03$, and more frequent need to wear stockings $p = 0.003$. Patients after the SLN procedure only were more content with the treatment they had undergone $p = 0.04$. Moreover, no differences in sexual activeness were observed between SLN procedure and inguinofemoral lymphadenectomy.

LoE 2+

Two smaller studies^{199,200} were also identified. As part of a prospective study enrolling 36 patients 12 SLN biopsy procedures and 24 inguinofemoral lymphadenectomies, Novackova *et al.*¹⁹⁹ observed an increased fatigue and impaired lymphoedema in patients after inguinofemoral lymphadenectomy. Among patients who underwent SLN biopsy procedures, none of the quality of life variables worsened postoperatively. In the second small study 5 SLN biopsy procedures and 10 inguinofemoral lymphadenectomies, Former *et al.*²⁰⁰ found that inguinofemoral lymphadenectomy had a negative impact on sexual function.

LoE 2-

Preferences of patients/acceptance of the SLN procedure: three identified studies^{198,201,202} assessed the preferences of women for SLN procedure versus inguinofemoral lymphadenectomy in the treatment of vulvar cancer. Acceptance of the SLN procedure depended on the false-negative rate:

LoE 2+

- Oonk *et al.*¹⁹⁸: when the false-negative rate was stated as 10%, 84% of patients who underwent a SLN procedure would recommend it, whereas only 48% of the patients who required the inguinofemoral lymphadenectomy advised it $p = 0.005$. These differences were also observed with a suggested false-negative rate of 1% 97% versus 62%, $p = 0.001$ and 0.1% 97% versus 71%, $p = 0.013$.
- de Hullu *et al.*²⁰¹: sixty-six per cent of the patients who had undergone inguinofemoral lymphadenectomy would recommend an inguinofemoral lymphadenectomy if the possibility of missing a lymph node metastasis with the SLN procedure was one out of 80 patients, while this proportion increased to 84% if the estimated risk was 10 out of 80. Their preference was not related to age or the side-effects they had experienced. Investigators also assessed the preferences on the acceptable false-negative rate of the SLN procedure in gynecologists treating patients with vulvar cancer. Sixty per cent of gynecologists were willing to accept a 5-20% false-negative rate of the SLN procedure.
- Farrell *et al.*²⁰²: if the risk of missing a positive lymph node was higher than 1 in 100, 80% of patients who had undergone inguinofemoral lymphadenectomy chose inguinofemoral lymphadenectomy and 15% of patients chose a SLN procedure 5% of patients were unable to make a decision. An association has been reported between the choice inguinofemoral lymphadenectomy or SLN procedure and the severity of lymphoedema. Of the 48 women choosing inguinofemoral lymphadenectomy, 4 reported moderate or severe lymphoedema, whereas of the 9 women choosing SLN procedure, 3 reported moderate or severe lymphoedema $p = 0.04$. But if the risk of missing a positive lymph node was lower than 1 in 100, almost one third of the women would prefer sentinel node biopsy.

10.2 Previous initiatives

Four previous initiatives^{2,3,39,88,203} presenting guidelines on SLN procedure were identified.

10.3 Development group comments

In tumours involving the midline, absence of bilateral drainage should be considered as a false negative procedure at the site of no drainage.

Multiple sectioning and immunohistochemistry allow more accurate evaluation of the SLN.

10.4 Guidelines

- B** The sentinel lymph node procedure is recommended in patients with unifocal cancers of < 4 cm, without suspicious groin nodes.
- B** Use of radioactive tracer is mandatory, use of blue dye is optional.
- C** Lymphoscintigram is advised to enable the preoperative identification, location and number of sentinel lymph nodes.
- C** Intraoperative evaluation and/or frozen sectioning of the sentinel lymph node can be performed in an attempt to prevent a second surgical procedure. Caution is warranted because of an increased risk of missing micrometastases on final pathology due to the loss of tissue arising from processing for frozen section assessment.
- ✓ When a sentinel lymph node is not found method failure, inguofemoral lymphadenectomy should be performed.
- C** Where metastatic disease is identified in the sentinel lymph node any size: inguofemoral lymphadenectomy in the groin with the metastatic sentinel lymph node.
- ✓ For tumours involving the midline: bilateral sentinel lymph node detection is mandatory. Where only unilateral sentinel lymph node detection is achieved, an inguofemoral lymphadenectomy in the contralateral groin should be performed.
- C** Pathological evaluation of sentinel lymph nodes should include serial sectioning at levels of at least every 200 µm. If the H&E sections are negative, immunohistochemistry should be performed.

Table 4. Pooled data on the test accuracy of various techniques for SLN assessment

Author ^{reference}	Year	Blue dye	99mTc	Blue dye/99mTc	Fluorescent materials with near infrared imaging
Detection rate <i>patient basis</i>					
Hassanzade <i>et al.</i> ⁸⁹	2013	78% 95% CI = 66 -86)	94% 95% CI = 89 -96)	95% 95% CI = 92 -97)	85% 95% CI = 68 -94)
Meads <i>et al.</i> ⁹⁰	2014	68.7% 95% CI = 63.1 -74.0)	94.0% 95% CI = 90.5 -96.4)	97.7% 95% CI = 96.6-98.5)	NA
Detection rate <i>groin basis</i>					
Hassanzade <i>et al.</i> ⁸⁹	2013	72% 95% CI = 62 -80)	88% 95% CI = 81 -92)	91% 95% CI = 87 -94)	85% 95% CI = 6 4-95
Sensitivity <i>patient basis</i>					
Hassanzade <i>et al.</i> ⁸⁹	2013	89% 95% CI = 65-99)	91% 95% CI = 81 -96)	95% 95% CI = 92 -98)	NA
Lawrie <i>et al.</i> ⁹¹	2014	94% 95% CI = 69 -99)	93% 95% CI = 89 -96)	95% 95% CI = 89 -97)	NA
Sensitivity <i>groin basis</i>					
Hassanzade <i>et al.</i> ⁸⁹	2013	86% 95% CI = 65 -97)	95% 95% CI = 87 -99)	95% 95% CI = 91 -97)	NA
Lawrie <i>et al.</i> ⁹¹	2014	92% 95% CI = 82 -97)	91% 95% CI = 87 -94)	94% 95% CI = 88 -97)	NA

NA: not available

Table 5. Pooled data published by Hassanzade *et al.*⁸⁹ on the test accuracy of SLN biopsy according to location of the tumour and inclusion of patients with palpable or suspicious inguinal nodes in the study population

Test accuracy	Location of the tumour		Inclusion of patients with palpable or suspicious inguinal nodes	
	Lateral tumours	Midline tumours	Yes	No
Detection rate <i>patient basis</i>	93% 95% CI = 88 -96)	95% 95% CI = 92 -97)	92% 95% CI = 86 -96	95% 95% CI = 92 -97)
Detection rate <i>groin basis</i>	93% 95% CI = 88 -96)	73% 95% CI = 67 -78)	77% 95% CI = 63 -88)	82% 95% CI = 76 -87)
Sensitivity <i>patient basis</i>	92% 95% CI = 79-98)	90% 95% CI = 87 -93)	90% 95% CI = 82 -96)	92% 95% CI = 88 -95)
Sensitivity <i>groin basis</i>	91% 95% CI = 75 -98)	94% 95% CI = 91 -97)	90% 95% CI = 78 -97)	92% 95% CI = 89 -95)

Table 6. Original studies presenting clinical parameters in patients treated by SLNB versus ILND

Author ^{reference}	Year	N	SLN biopsy	ILND	p-value
Operation time					
Brammen <i>et al.</i> ¹⁷¹	2015	128	76.2 min ¹	103.3 min ¹	< 0.001
Hefler <i>et al.</i> ¹⁷⁸	2008	75	85.5 min	120.7 min	0.002
Hospital stay					
Brammen <i>et al.</i> ¹⁷¹	2015	128	13.3 days	18.1 days	0.006
Hefler <i>et al.</i> ¹⁷⁸	2008	75	12.6 days	22.9 days	< 0.001
van der Zee <i>et al.</i> ¹⁴⁵	2008	403	8.4 days ²	13.7 days ²	< 0.0001
Inguinal drainage					
Brammen <i>et al.</i> ¹⁷¹	2015	128	4.1 days	6.9 days	< 0.001
Hefler <i>et al.</i> ¹⁷⁸	2008	75	3.3 days	6.9 days	< 0.001

¹ mean value, ² median value

11 Radiation therapy

11.1 Summary of available scientific evidence

Primary radiotherapy of the groin: as part of Cochrane systematic review, van der Velden *et al.*²⁰⁴ compared the effectiveness and safety of this therapeutic approach to the inguino-femoral lymph nodes with primary groin surgery. One randomised controlled trial²⁰⁵, one case-control²⁰⁶ and two observational^{186,207} studies have been included in this review. No pooled analysis is described and it should be noted that two studies also included patients with non-squamous histology^{206,207}. The tumour recurrence rate in the groin after primary groin radiation ranged from 0% to 18.5% **Table 7**. However, only the randomised controlled trial²⁰⁵ directly compared radiotherapy towards the groin versus surgery. In this trial, there is a difference in groin recurrence, favouring the primary groin surgery 0% versus 18.5%. Overall survival and progression-free survival were significantly lower in the radiation group compared with the surgery group $p = 0.04$ and $p = 0.03$, respectively. But, the patients treated with groin radiation had substantially shorter hospitalizations than those who underwent groin surgery $p = 0.0001$. It should be noted that this trial was closed prematurely when interim monitoring revealed an excessive number of groin relapses on the groin radiation regimen. Criticisms could be made of the technique of radiotherapy applied in this trial potential insufficiency to sterilise subclinical lymph node metastases in the groin. Maximum dose was prescribed at 3 cm in this trial. It is likely, therefore, that the deeper groin nodes were relatively undertreated.

LoE 1-

Neoadjuvant radiotherapy: no studies enrolling at least 50 patients were identified. Interpretation of the results from the 8 identified trials²⁰⁸⁻²¹⁵ are limited notably by the small number of patients evaluated only 3 trials²⁰⁸⁻²¹⁰ have accrued in excess of 10 patients and by the heterogeneity in the radiotherapy regimens external beam radiation and/or intracavitary brachytherapy. Although studies are very small, authors reported low severe complications and high proportions of patients alive with no evidence of disease and no recurrence **Table 8**. Furthermore, this combined therapeutic approach showed a good probability of bladder and/or rectal preservation.

LoE 3

Adjuvant radiotherapy c lose surgical margins or positive margins: Faul *et al.*²¹⁶ reported a reduction of local recurrence from 58% to 16% in these patients treated with adjuvant radiation therapy. On multivariate analysis, adjuvant radiation was a significant prognostic predictor for local control $p = 0.009$. However, it did not reach statistical significance for overall survival. On subgroup analysis, adjuvant radiation therapy significantly improved actuarial 5-year survival for patients with positive margins $p = 0.001$, but not for those with close margins $p = 0.63$.

LoE 2+

Adjuvant radiotherapy n o suspicious groin nodes: Stehman *et al.*²⁰⁵ randomised 58 patients patients with lesions clinically confined to the vulva and no suspicious groin nodes to either radical vulvectomy followed by either groin radiation or inguinal lymphadenectomy plus groin radiation if nodes were involved to compare efficacy and morbidity of the two treatment approaches. The groins were treated daily to a dose of 50 Gy over 5 weeks 200 cGy/d. Patients randomised to the groin dissection arm who were found to have metastatic carcinoma in the resected nodes received post-operative radiation therapy to the ipsilateral groin and hemipelvis. A total dose of 50 Gy was administered through anterior portals to the groin and through anterior and posterior portals to the iliac nodes. The study was closed prematurely when interim monitoring revealed an excessive number of groin relapses on the groin radiation regimen see above.

LoE 1-

Adjuvant radiotherapy s ingle positive node: the benefit of adjuvant radiation in patients with a single lymph node metastasis and micrometastatic disease to the lymph nodes is controversial. Fons *et al.*²¹⁷ could not demonstrate a significant benefit of adjuvant radiotherapy in these patients on both disease-free and disease-specific survival $HR = 0.98$, 95% CI = 0.45 -2.14, $p = 0.97$ and $HR = 1.02$, 95% CI = 0.42-2.47, $p = 0.96$. Recurrence rates appeared quite similar between the radiotherapy

LoE 2+

and the no-radiotherapy group 39% versus 32%. In multivariate subanalysis performed as part of the AGO-CaRE-1 study²¹⁸ 163 patients, adjuvant radiotherapy was associated with a not statistically significant better PFS compared to patients without adjuvant treatment adjustment for age, Eastern cooperative oncology group ECOG performance status, Union internationale contre le cancer UICC stage, grade, and invasion depth: HR = 0.88, 95% CI = 0.50-1.56, p = 0.67. Similar results were obtained after control for multiple confounding factors by inverse probability of treatment weighting HR_{IPW} = 0.93, 95% CI = 0.51-1.67, p = 0.79.

Parthasarathy *et al.*²¹⁹ have for their part reported a favourable 5-y disease specific survival DSS in patients receiving adjuvant radiation. Controlling for age at diagnosis and extent of lymphadenectomy, their data suggest that adjuvant radiation may improve the survival of these patients although this only reached borderline statistical significance HR = 0.57, 95% CI = 0.32 - 1.03, p = 0.06. However, it should be noted that no information about the size and location of tumour is available in this study. Moreover, adjuvant radiation did not significantly benefit women who had more than 12 nodes resected 66.7 versus 77.3%, p = 0.23.

Adjuvant radiotherapy multiple positive nodes : a randomised trial compared pelvic radiotherapy with pelvic lymphadenectomy in 114 patients with inguinofemoral lymph node metastases after radical vulvectomy and bilateral inguinofemoral lymphadenectomy²²⁰. The difference in regional groin recurrence was significant, favouring the adjunctive radiation therapy group 5.1% versus 23.6%, p = 0.02. Survival proved also to be better in the patients who received postoperative radiotherapy overall survival p = 0.03, relative survival 0.004, progression-free interval 0.03. In this study, the most dramatic survival advantage for radiation therapy was in patients who had either of the two major poor prognostic factors present: 1 clinically suspicious or fixed ulcerated groin nodes, and 2 two or more positive groin nodes. The long time results of this trial revealed a persistent benefit for patients treated with pelvic irradiation²²¹.

LoE 1+

After a median survival follow-up of 74 months, the OS benefit for radiation in patients with clinically suspected or fixed ulcerated groin nodes p = 0.04 and two or more positive groin nodes p < 0.001 persisted. The relative risk of progression was significantly reduced in radiation patients HR = 0.39, 95% CI = 0.17-0.88, p = 0.02 after adjustment for age and adverse tumour characteristics. Moreover, the cancer-related death rate was significantly higher for pelvic node resection compared with radiation HR = 0.49, 95% CI = 0.28-0.87, p = 0.015. The proportion of patients developing post-operative wound infections, urinary tract infection, and other adverse sequelae were similar between treatment approaches. However, it should be noted that patients with positive groin nodes in the surgery group in this study did not receive adjuvant radiotherapy to the groins.

In multivariate analysis of different nodal subgroups performed as part of the AGO-CaRE-1 study²¹⁸ adjustment for age, ECOG performance status, UICC stage, grade, and invasion depth adjuvant radiotherapy was associated with statistically significant better progression-free survival PFS in patients with two positive nodes 91 patients, HR = 0.31, 95% CI 0.14-0.71, p = 0.005, and in patients with three positive nodes 56 patients, HR = 0.40, 95% CI = 0.16-0.98, p = 0.05 compared to patients without adjuvant treatment. Similar results were obtained after control for multiple confounding factors by inverse probability of treatment weighting two positive nodes: HR_{IPW} = 0.24, 95% CI = 0.11-0.56, p < 0.001; three positive nodes: HR_{IPW} = 0.32, 95% CI = 0.13-0.79, p = 0.009. The benefit of adjuvant radiotherapy among patients with more than three positive nodes did not reach statistical significance 21 patients, HR = 0.52, 95% CI = 0.24-1.10, p = 0.09/HR_{IPW} = 0.44, 95% CI = 0.17-1.17, p = 0.10.

LoE 2+

11.2 Previous initiatives

Eight previous initiatives^{1-4,37-39,87} presenting guidelines on radiation therapy were identified.

11.3 Development group comments

When possible without damaging structures such as anus, urethra and clitoris, reexcision is preferred in case of positive margins in the light of the significant short as well as long term morbidity associated with the necessary relatively high dose of radiotherapy to the vulvar skin.

11.4 Guidelines

- ✓ Adjuvant radiotherapy should start as soon as possible, preferably within 6 weeks of surgical treatment.
- ✓ When invasive disease extends to the pathological excision margins of the primary tumour, and further surgical excision is not possible, postoperative radiotherapy should be performed.
- ✓ In case of close but clear pathological margins, postoperative vulvar radiotherapy may be considered to reduce the frequency of local recurrences. There is no consensus for the threshold of pathological margin distance below which adjuvant radiotherapy should be advised.
- B** Postoperative radiotherapy to the groin is recommended for cases with > 1 metastatic lymph node and/or presence of extracapsular lymph node involvement.
- ✓ Adjuvant radiotherapy for metastatic groin nodes should include the ipsilateral groin area and where pelvic nodes are non-suspicious on imaging, the distal part of the iliac nodes with an upper limit at the level of the bifurcation of the common iliac artery.
- C** Based on evidence from other squamous cell cancers such as cervical, head & neck, and anal cancer, the addition of concomitant, radiosensitising chemotherapy to adjuvant radiotherapy should be considered.

Table 7. Original studies presenting data in patients treated with primary groin radiation

Author ^{reference}	Year	N	Radiotherapy regimen	Groin recurrence	Survival
Stehman <i>et al.</i> ²⁰⁵	1992	52	Dose: 50 Gy at 3 cm Type: 50% electrons	Radiation: 18.5% 5/27) Surgery: 0% 0/25)	Median follow-up: > 36 months OS: 60% versus 86% DSS: 67% versus 92% DFS: 68% versus 92%
Manavi <i>et al.</i> ²⁰⁶	1997	135	Dose: 45 Gy at 5 cm Type: telecobalt	Radiation: 4.6% 6/65) No radiation: 10% 7/70)	Follow-up: NA 5y-OS: 62.4% versus 93.7%
Katz <i>et al.</i> ¹⁸⁶	2003	14	Dose: 45 Gy Type: electrons and photons combined	0% 0/14	Median follow-up: 98 months
Perez <i>et al.</i> ²⁰⁷	1998	19	Dose: 50-70 Gy at 4 cm Type: photons electron boost	10.5% 2/19	Median follow-up: 60 months

5y-OS: 5-year overall survival, DFS: disease-free survival, DSS: disease-specific survival, Gy: Gray, NA: not available, OS: overall survival.

Table 8. Original studies presenting data in patients treated with neoadjuvant radiation

Author ^{reference}	Year	N	Radiotherapy regimen	Recurrence	Survival/complications
Boronow <i>et al.</i> ²⁰⁸	1987	37	External beam and intracavitary: N = 22 Intracavitary only: N = 12 External beam only: N = 3	Local: N = 5 Pelvic: N = 1	Median follow-up: 38.4 months Status: 59.5% 2 2/37 alive NED Severe complications: 23%
Balat <i>et al.</i> ²⁰⁹	2000	24	External beam: N = 24	Local: N = 5 Distant: N = 1	Median follow-up: NA Status: 70.8% 17/24) alive NED Severe complications: NA
Rotmensch <i>et al.</i> ²¹⁰	1990	16	External beam: N = 16	Central: N = 4 Distant: N = 2	Median follow-up: 25 months Status: 56.3% 9/16 alive NED Severe complications: 4%
Hacker <i>et al.</i> ²¹¹	1984	8	External beam and intracavitary: N = 1 External beam only: N = 7	NA	Median follow-up: NA Status: 62.5% 5/8 alive NED Severe complications: 12%
Jafari <i>et al.</i> ²¹²	1981	4	External beam: N = 4	Local: N = 0 Distant: N = 0	Median follow-up: NA Status: 100% 4/4 alive NED Severe complications: 0%
Fairey <i>et al.</i> ²¹³	1985	7	External beam: N = 7	Local: N = 1 Distant: N = 1	Median follow-up: NA Status: 85.7% 6/7) alive NED Severe complications: 14%
Carlino <i>et al.</i> ²¹⁴	1984	6	Intracavitary: N = 6	Local: N = 2	Median follow-up: NA Status: NA Severe complications: NA
Pao <i>et al.</i> ²¹⁵	1988	2	NA	NA	Median follow-up: NA Status: 100% 2/2 alive NED Severe complications: 0%

NA: not available, NED: no evidence of disease and no recurrence.

12 Chemoradiation

12.1 Summary of available scientific evidence

Primary chemoradiation: as part of Cochrane systematic review, Shylasree *et al.*²²² evaluated the effectiveness and safety of neoadjuvant and primary chemoradiation for women with LAVC. Among the 3 studies included in this review²²³⁻²²⁵, only two retrospective studies^{224,225} looked at primary chemoradiation versus primary surgery. It should be noted that no pooled analysis is described. The number of cases of tumour recurrence and deaths were too small in one study²²⁵ to allow computing an adjusted hazard ratio the confidence interval was non-informative for all combinations of covariate adjustment). In the second retrospective study, Landrum *et al.*²²⁴ compared outcomes of 63 patients with LAVC treated by primary surgery N = 30 of by primary chemoradiation N = 33. The general schema for chemoradiation involved weekly cisplatin 40 mg/m² or two cycles of cisplatin 50 mg/m² plus 5 -FU 1,000 mg/m² concurrent with external beam radiation. The radiation fraction size was generally 160-180 cGy delivered in a once-daily fraction with a median dose of 4,760 cGy range 3,690 -6,300 cGy to the whole pelvis and primary vulvar site, with additional radiation to the inguinal regions as directed by nodal status. Patients were managed surgically with radical N = 11 or modified radical vulvectomy N = 19 when adequate surgical margins could be obtained without urinary or colonic diversion. Adjuvant radiation or chemoradiation was completed in 19 of 25 patients in the primary surgery group with lymph node metastasis. Eight patients had surgical excision of residual disease following primary chemoradiation.

LoE 2+

At a median follow-up of 31 months, there was no statistically significant difference in the risk of death in patients with LAVC between patients who received primary chemoradiation and those who received primary surgery, after adjustment for age, FIGO stage, size of tumour and nodal status HR = 1.09, 95% CI = 0.37-3.17, p > 0.05. Recurrence or PFS was not reported in a multivariate analysis in this study. However, the authors reported no statistically significant difference in recurrence rate based on treatment group 5 in the chemoradiation arm versus 7 in the primary surgery arm, p > 0.05. Four patients that were treated with primary chemoradiation only had a partial response to treatment and died of the disease.

Another study enrolling at least 50 patients has been identified. In a GOG phase II study including 58 patients with LAVC not amenable to surgical resection radical vulvectomy, Moore *et al.*²²⁶ assessed the efficacy and toxicity of radiation therapy and concurrent chemotherapy when used for the primary treatment. Radiation was given daily, five days per week in 1.8 Gy fractions to a total dose of 57.6 Gy. Patients received concurrent cisplatin 40 mg/m² to maximum dose 70 mg chemotherapy administered weekly throughout radiation therapy. Patients only underwent radical surgical resection after chemoradiation if they had residual disease present on biopsy. After a median follow-up of 24 months, 37 patients 64% achieved a cCR. Among these patients there were 29 50% who underwent surgical biopsy and had a pCR Table 9. Twenty-two of these 29 patients continued to have no evidence of disease, while 7 patients experienced recurrence. Of the 29 patients who had persistent disease after chemoradiation and who underwent surgical resection, 8 28% were alive at last follow-up with no evidence of disease recurrence. Although acute toxicity was significant, the protocol was considered tolerable.

Results from the 16 other identified studies²²⁷⁻²⁴² are limited notably by the small number of patients evaluated only 2 trials^{231,232} have accrued in excess of 20 patients and by the heterogeneity in the primary chemoradiation regimens. Although studies are small, chemoradiation as a primary therapeutic approach has been reported to produce high response rates Table 9.

LoE 3

Neoadjuvant chemoradiation: among the 3 studies²²³⁻²²⁵ included in the Cochrane systematic review published by Shylasree *et al.*²²², only one study²²³ looked at neoadjuvant chemoradiation versus

LoE 1-

primary surgery. In this randomised controlled trial, 68 women with operable LAVC were randomised to either primary radical surgery followed by radiation if more than one groin lymph node contained metastatic disease, or to neoadjuvant chemoradiation followed by surgery. Chemoradiation comprised 50 Gy neoadjuvant radiotherapy with concurrent infusional 5-FU 750 mg/m² days 1-5 and Mitomycin-C 15 mg/m² IV day 1, with two courses given three weeks apart. In the primary surgery arm, 15/37 patients underwent adjuvant radiation. Surgery was feasible in 24 out of 28 patients in the neoadjuvant arm. At a mean follow-up of 42 months, thirty recurrences have been reported 13 in the neoadjuvant chemoradiation arm and 17 in the primary surgery arm. The authors reported no statistically significant difference in the risk of death at 5 years between the two therapeutic approaches RR = 1.39, 95% CI = 0.94-2.06, p > 0.05. Furthermore, no statistically significant difference in the risk of overall treatment related morbidity was found RR = 1.18, 95% CI = 0.71-1.96, p > 0.05. It should be noted that details regarding the extent of primary tumour and the complexity of surgical procedures required in each group are not provided, and quality of life is not reported.

Two other original studies^{243,244} enrolling at least 50 patients were identified. In a GOG phase II study including 71 patients with unresectable vulvar disease, or disease requiring exenterations, Moore *et al.*²⁴³ investigated the role of concurrent radiotherapy and cisplatin/infusional 5-FU chemotherapy. A cCR occurred in 47% of patients. Among those patients who had surgery, 70% had a pCR. Two of 71 patients had unresectable disease after chemoradiation, and three patients required exenteration. After a median follow-up of 50 months, 40 patients were alive with no evidence of disease and no recurrence **Table 10**. Toxicity from chemoradiation was estimated acceptable, although acute cutaneous reactions were almost universal. In the second identified study²⁴⁴, 58 patients referring for primary or recurrent disease received preoperative radiotherapy to a dose of 54 Gy divided into two courses with an interval of two weeks. Concurrent preoperative chemotherapy with 5-FU 750 mg/m² daily for 5 days and Mitomycin -C 15 mg/m² single bolus were given at the start of each cycle. A cCR of both the vulvar and inguinal disease occurred in 27% of patients. A pCR was confirmed in 13 patients 31%. After a median follow-up of 22 months, 28 patients were alive with no evidence of disease and no recurrence **Table 10**. Like the GOG phase II study²⁴³, treatment side effects were estimated acceptable.

LoE 2+

As part of a meta-analysis including 7 studies^{229,234,237,245-248} for a total of 70 patients, Stuckey *et al.*²⁴⁹ investigated whether elderly patients are more likely to die of intercurrent disease or of treatment complications. It should be noted that Stuckey *et al.*²⁴⁹ included patients receiving preoperative or primary chemoradiation treatment with curative intent even if in the majority of cases, this was given with neoadjuvant intent. Radiation doses ranged from 18 to 72 Gy and included the vulvar, inguinal, and the pelvic regions. Chemotherapy included 5-FU with or without cisplatin or Mitomycin-C **Table 11**. Seventy-eight percent of patients younger than 65 years were without evidence of disease after treatment versus 66% of patients aged 65 years and above. Three percent of patients younger than 65 years of age died of intercurrent disease or treatment-related complications versus 11% of patients aged 65 years and above. But these differences did not reach statistical significance p = 0.30 and p = 0.37, respectively. It should be noted that 1 the small sample size from included studies and 2 the changes in radiation therapy techniques and chemotherapy could make it difficult to statistically support the trend showing that elderly patients have lower survival and higher intercurrent death.

LoE 1-

Results from the 11 other identified studies^{233,242,245-247,250-255} are limited notably by the small number of patients evaluated only 4 studies^{242,250,252,253} have accrued in excess of 20 patients and by the heterogeneity in the chemotherapy regimens used in the neoadjuvant setting along with radiation therapy **Table 10**. Although studies are small, chemoradiation as a neoadjuvant therapeutic approach has been reported to produce high response rates and high rates of surgical resectability without exenteration, regardless of chemotherapy regimen used. Overall, authors described high but

LoE 3

manageable rates of vulvar cutaneous toxicity.

Adjuvant chemoradiation: only one study²⁵⁶ enrolling at least 50 patients was identified. As part of a large population-base analysis, Gill *et al.*²⁵⁶ evaluated adjuvant chemotherapy for node-positive vulvar cancer patients who received adjuvant radiotherapy. All patients N = 1,797 received external beam radiotherapy as their radiotherapy treatment modality. Radiation modality was available for 35.7% of patients. For those with modality captured, intensity-modulated radiotherapy was utilized in 6.5%. Median radiotherapy dose was 54 Gy. Median radiation length and time to chemotherapy initiation were 44 days and 76 days, respectively. Of patients receiving chemotherapy, 78.5% started chemotherapy within 7 days of the start of radiotherapy.

LoE 2-

After a median follow-up of 28.3 months, the unadjusted median survival without N = 1,324 and with adjuvant chemotherapy N = 473 was 29.7 months and 44 months p = 0.001, respectively. On multivariate analysis, delivery of adjuvant chemotherapy resulted in a trend towards reduction in the risk of death among patients who received adjuvant radiotherapy HR = 0.81, 95% CI = 0.65 -1.01, p = 0.059. On regression modeling with a n adjustment using propensity score with IPTW, Gill *et al.*²⁵⁶ reported a statistically significant reduction in the risk of death for patients who received adjuvant chemotherapy HR_{IPTW} = 0.62, 95% CI = 0.48-0.79, p < 0.001.

Results from the 4 other identified studies^{225,230,231,236} are limited notably by the very small number of patients evaluated. No study has accrued in excess of 10 patients **Table 12**.

LoE 3

12.2 Previous initiatives

Seven previous initiatives^{1,2,4,37-39,87} presenting guidelines on chemoradiation were identified.

12.3 Development group comments

None.

12.4 Guidelines

- C** Definitive chemoradiation with radiation dose escalation is the treatment of choice in patients with unresectable disease.
- C** In advanced stage disease neoadjuvant chemoradiation should be considered in order to avoid exenterative surgery.
- C** Radiosensitising chemotherapy, preferably with weekly cisplatin, is recommended.

Table 9. Original studies presenting response and survival data in patients treated with primary chemoradiation

Author ^{reference}	Year	N	Chemotherapy regimen	Radiotherapy regimen	Response	Survival
Moore <i>et al.</i> ^{a,226}	2012	LAVC: N = 58	Weekly CisP 40 mg/m ² IV, up to 7 cycles	57.6 Gy in 1.8 Gy daily fractions	cCR: 64% 37/58 pCR: 50% 29/58)	Median follow-up: 24 months Status: 51% 30/58 alive NED Recurr. 24% 7/29) with pCR
Landrum <i>et al.</i> ²²⁴	2008	LAVC: N = 33	Either weekly CisP 40 mg/m ² or two cycles of CisP 50 mg/m ² IV d1 + 5-FU 1,000 mg/m ² IV d1-4	47.6 Gy in 1.8 Gy daily fractions	CR: 87% 29/33	Median follow-up: 31 months Status: NA Recurr.: 17% 5/29) with CR
Mak <i>et al.</i> ²³¹	2011	LAVC : N = 24	Either weekly CisP or 3-4 week 5-FU based regimens	50 Gy, timing of fractions varied	CR: 58% 20/34 ^b	Median follow-up: 31.5 months Status: NA Recurr.: NA
Leiserowitz <i>et al.</i> ²³²	1997	LAVC : N = 23	5-FU 1,000 mg/m ² infusion d1-4 + CisP 100 mg/m ² IV d2, given 2-3 times during radiotherapy	Vulvar and inguinal region. 54 Gy in 1.8 Gy BID fractions	CR : 78% 18/23)	Mean follow-up: 45 months Status: 60% 14/23 alive NED Recurr.: 17% 4/23)
Tans <i>et al.</i> ²²⁸	2011	LAVC : N = 20	5-FU 1,000 mg/m ² infusion d1-4 + MMC 10 mg/m ² IV d1, given first week of each course of radiotherpay	Split course 40 Gy + 20 Gy in 2 Gy fractions with 2-week break	CR: 70% 14/20	Median follow-up: NA Status: NA Recurr.: NA
Wahlen <i>et al.</i> ²³⁴	1995	LAVC : N = 19	5-FU 1,000 mg/m ² infusion d1-4 given weeks 1 + 5 of radiotherapy. Six pts also given MMC 10 mg/m ² IV d1	45-50 Gy in 1.8 Gy daily fractions + implant or electron boost to vulva	CR: 52% 10/19 PR : 36% 7/19	Median follow-up: 34 months Status: 79% 15/19 alive NED Recurr.: 10% 1 /10) with CR
Russel <i>et al.</i> ²²⁹	1992	LAVC: N = 18	5-FU 750-1,000 mg/m ² infusion d1-4 + CisP 100 mg/m ² IV d1, 2-3 cycles given	54 Gy for macro and 36 Gy for microscopic disease	CR: 50% 9/18 pCR: 44% 8/18 PR: 6% 1/18)	Median follow-up: 24 months Status: 67% 12/18 alive NED Recurr.: 11% 2/18
Sebag-Montefiore <i>et al.</i> ²²⁷	1994	LAVC: N = 16	5-FU 750 mg/m ² infusion d1-5 + MMC 10 mg/m ² IV d1, given first 5 d and last 5 d of radiotherapy	45 Gy in 2-2.5 Gy daily fractions	CR : 44% 7/16) PR : 37% 6/16	Follow-up: NA Status: NA Recurr.: NA
Koh <i>et al.</i> ²³³	1993	LAVC: N = 14	5-FU 750-1,000 mg/m ² IV infusion d1-4, weekly for 3 cycles	54 Gy in either daily or BID fractions	CR: 57% 8/14 PR: 36% 5/14	Median follow-up: 27 months Status: 50% 7/ 14 alive NED Recurr. 7% 1/14
Cunningham <i>et al.</i> ²³⁵	1997	LAVC : N = 14	5-FU 1000 mg/m ² infusion d1-4 + CisP 50 mg/m ² d1, given on first and last week of radiotherapy	45-50 Gy plus vulvar boost of 9-14 Gy	CR : 64% 9/14) PR : 29% 4/14	Mean follow-up: 26 months Status: 28% 4/14 alive NED Recurr. : 11% 1/9 with CR
Iversen <i>et al.</i> ²³⁸	1982	LAVC: N = 9 Recur.: N =4	Bleo 30 mg IM d 1, 3, 5 repeated after 2 weeks	36-40 Gy in 3 Gy daily fractions	NA	Follow-up: 112 months Status: 30% 4/13 alive NED Recurr. : NA

^a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, ^b treatment response among the 34 patients treated with initial chemoradiation data not available for patients treated by primary chemoradiation specifically), 5-FU: 5-fluorouracil, cCR: clinical complete response, CR: complete response, CisP: cisplatin, Gy: Gray, LAVC: locally advanced vulvar cancer, MMC: mitomycin C, NA: not available, NED: no evidence of disease and no recurrence, pCR: pathologic complete response, PR: partial response, Recurr.: recurrence.

Original studies presenting response and survival data in patients treated with primary chemoradiation *continued*

Author ^{reference}	Year	N	Chemotherapy regimen	Radiotherapy regimen	Response	Survival
Han <i>et al.</i> ²³⁶	2000	LAVC : N = 12	5-FU 1,000 mg/m ² infusion d1-4 + MMC 10 mg/m ² IV d1, given week 1 and 5 of radiotherapy	45 Gy vulva, pelvic and inguinal lymph nodes, 6 - 17 Gy to gross disease	CR: 42% 5/12 PR: 58% 7/12)	Follow-up: NA Status: NA Recurr.: NA
Berek <i>et al.</i> ^{a,237}	1991	LAVC: N = 12	5-FU 1,000 mg/m ² infusion d1-4 + CisP 100 mg/m ² d1 every 28 d for 2 cycles	40-52 Gy in 1.6-1.8 Gy daily fractions, with boost to vulva up to 74 Gy	CR: 67% 8/12 PR: 25% 3/12)	Median follow-up: 37 months Status: 83% 10/12 alive NED Recurr.: 17% 2/12
Akl <i>et al.</i> ²³⁹	2000	NA: N = 12	5-FU 1,000 mg/m ² /24h as continuous infusion days 1–4 and 29-32 + MMC 15 mg/m ² IV day 1	Vulva only all pts node negative. 30 –36 Gy in 2 Gy daily fractions	CR: 100% 12/12)	Mean follow-up: 41 months Status: 66% 8/12 alive NED Recurr.: 16% 2/12)
Thomas <i>et al.</i> ²³⁰	1989	LAVC: N = 9	5-FU 1,000 mg/m ² infusion d1-4 ± MMC 6 mg/m ² 4/6 one injection, and 2/6 two injections 4 weeks apart	40-64 Gy in 1.6-1.8 Gy twice daily fractions	CR: 67% 6/9	Median follow-up: 20 months Status: 67% 6/9) alive NED Recurr.: NA
Beriwal <i>et al.</i> ²⁴²	2013	LAVC: N = 9	CisP 40 mg/m ² d1 N = 6) and 5 -FU 1,000 mg/m ² infusion, d1-5 N = 36). Two cycles, given the first and last week of radiotherapy	IMRT 46 Gy in 1.6 Gy BID fractions for 5d, then 1.8 Gy daily for 7-8d then a break of 10-14 d, then 1.6 Gy BID for 5 d	cCR: 44.4% 4/9)	Follow-up: NA Status: NA Recurr.: NA
Mulayim <i>et al.</i> ²²⁵	2004	LAVC : N = 7	5-FU 1,000 mg/m ² infusion d1-4 + MMC 10 mg/m ² IV d1, given weeks 1 and 4 of radiotherapy	60 Gy for macro and 45 Gy for microscopic disease	CR: 85% 6/7	Median follow-up: 31 months Status: 42% 3/7) alive NED Recurr.: 28% 2/7)
Evans <i>et al.</i> ^{a,240}	1988	LAVC: N = 4	5-FU 1,000 mg/m ² continuous infusion d1-4 + MMC 10 mg/m ² IV d1	25-50 Gy in 2 Gy daily fractions	CR: 50% 2/4 PR: 50% 2/4)	Mean follow-up: 33 months Status: 50% 2/4) alive NED Recurr.: 0% 0/3
Kalra <i>et al.</i> ^{a,241}	1985	LAVC: N = 2	MMC 10 mg/m ² IV d1 + 5-FU 1,000mg/m ² infusion d1-5, given weeks 1 and 4 of radiotherapy	50 Gy in 2 Gy daily fractions	CR: 100% 2/2	Mean follow-up: 33 months Status: 100% 2/2 alive NED Recurr.: 0% 0/2

^a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, 5-FU: 5-fluorouracil, Bleo: bleomycin, CR: complete response, CisP: cisplatin, Gy: Gray, LAVC: locally advanced vulvar cancer, MMC: mitomycin C, NA: not available, NED: no evidence of disease and no recurrence, PR: partial response, Recurr.: recurrence.

Table 10. Original studies presenting data in patients treated with neoadjuvant chemoradiation

Author ^{reference}	Year	N	Chemotherapy regimen	Radiotherapy regimen	Response	Survival
Moore <i>et al.</i> ^{a,243}	1998	LAVC: N = 71	5-FU 1,000 mg/m ² infusion d1-4 + CisP 50 mg/m ² IV d1, given week 1 of each course of radiotherapy	2 courses of 23.8 Gy, given as 1.7 Gy BID for 4 days and daily for 6 days with 2 weeks break	CR: 47% 34/71	Median follow-up: 50 months Status: 56% 40/71 alive NED Recurr.: 34% 24/69)
Landoni <i>et al.</i> ^{a,244}	1996	LAVC: N = 41 Recurr.: N = 17	5-FU 750 mg/m ² infusion d1-5 + MMC 15 mg/m ² IV d1 given week 1 of each course of radiotherapy	54 Gy in 2 courses 36 Gy + 18 Gy with 14 d treatment break	cCR: 27% 14/52 pCR: 31% 13/42)	Median follow-up: 22 months Status: 48% 28/58 alive NED Recurr.: 27% 16/58)
Montana <i>et al.</i> ^{a,250}	2000	LAVC: N = 46	5-FU 1,000 mg/m ² infusion d1-4 + CisP 50 mg/m ² IV d1, given week 1 of each course of radiotherapy	2 courses of 23.8 Gy, given as 1.7 Gy BID for 4 days and daily for 6 days with planned 2 weeks break	pCR nod es: 40% 15/37 pCR vulva: 52% 20/38)	Median follow-up: 78 months Status: 26% 12/46 alive NED Recurr.: 51% 19/37)
Beriwal <i>et al.</i> ^{a,242}	2013	LAVC: N = 42	CisP 40 mg/m ² d1 N = 6) and 5 -FU 1,000 mg/m ² infusion, d1-5 N = 36. Two cycles, given the first and last week of radiotherapy	IMRT 46 Gy in 1.6 Gy BID fractions for 5d, then 1.8 Gy daily for 7-8d then a break of 10-14 d, then 1.6 Gy BID for 5 d	cCR: 51.2% 21/41 pCR: 48.5% 16/33 pCR: 48.8% 20/41	Median follow-up: 15 months Status: 45.5% 15/33) alive NED Recurr.: 24.2% 8/33)
Lupi <i>et al.</i> ^{a,252}	1996	LAVC: N = 24	5-FU 750 mg/m ² infusion d1-5 + MMC 15 mg/m ² IV d1, given for 2 cycles	54 Gy in 2 courses with 14 d treatment break	CR: 42% 10/24 PR: 54% 13/24) pCR: 36% 8/22	Median follow-up: 34 months Status: 65.5% 15/24) ali ve NED Recurr.: 29% 7/24)
Gaudineau <i>et al.</i> ^{a,253}	2012	LAVC: N = 22	Carbo AUC 2 weekly during radiotherapy	50 Gy in 2 Gy daily fractions	pCR: 27% 6/22 ORR: 95% 21/22)	Median follow-up: 28 months Status: 54% 12/2 alive NED Recurr.: 32 % 7/22
Scheistroen <i>et al.</i> ^{a,251}	1993	LAVC: N = 20	Bleo 30 mg IV d1, 3, 5 during weeks 1 + 3 of radiotherapy	30-45 Gy in 3 Gy daily fractions	CR: 25% 5/20 PR: 50% 10/20)	Follow-up: NA Status: 5% 1/20) alive NED Recurr.: 80% 4/5) of pts with CR
Gerszten <i>et al.</i> ^{a,254}	2005	LAVC: N = 18	5-FU 1,000 mg/m ² infusion d1-4 + CisP 50 mg/m ² IV d1, given first and last week of radiotherapy	44.6 Gy in 1.6 Gy BID fractions for 5 d, then 1.8 Gy daily for 7d, with 1-2 weeks break, then 1.6 Gy BID for 5 d	cCR: 72% 13/18 pCR: 39% 7/18	Mean follow-up: 24 months Status: 83% 15/18 alive NED Recurr.: 17% 3/18)
Eifel <i>et al.</i> ^{a,245}	1995	LAVC: N = 12	CisP 4 mg/m ² /d infusion d1-4 + 5-FU 250 mg/m ² /d infusion d1-4, given weekly for 4 weeks	40 Gy in 2 Gy daily fractions	CR: 50% 6/12 PR: 41% 5/12)	Mean follow-up: 18 months Status: 50% 6/12 alive NED Recurr.: 16% 1/6) of pts with CR
Whitaker <i>et al.</i> ^{a,246}	1990	LAVC: N = 9 Recurr.: N = 3	5-FU 750-1,000 mg/m ² infusion d1-4 + MMC 10-12 mg/m ² IV d1, week 1 of each course of radiotherapy	25 Gy in 2.5 Gy fractions	CR : 42% 5/12) PR : 58% 7/12	Follow-up: NA Status: 25% 3/12 alive NED Recurr.: 60% 3/5) of pts with CR

^a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, 5-FU: 5-fluorouracil, AUC: area under the curve, BID: twice a day, Carbo: carboplatin, cCR clinical complete response, CisP: cisplatin, cPR clinical partial response, CR: complete response, d: days, Gy: Gray, IMRT: intensity-modulated radiation therapy, LAVC: locally advanced vulvar cancer, MMC: mitomycin C, NA: not available, NED: no evidence of disease and no recurrence, ORR: overall response rate, pCR: pathologic complete response, PR: partial response, pts: patients, Recurr: recurrence.

Original studies presenting data in patients treated with neoadjuvant chemoradiation *continued*

Author ^{reference}	Year	N	Chemotherapy regimen	Radiotherapy regimen	Response	Survival
Carson <i>et al.</i> ^{a,255}	1990	LAVC: N = 6 Recurr.: N = 2	5-FU 750 mg/m ² infusion d1-5 + MMC 7.5 mg/m ² IVd4 + CisP 0mg/m ² IV d1, given weekly during radiotherapy.	45-50 Gy in 1.75 Gy daily fractions	pCR: 75% 6/8	Mean follow-up: 10 months Status: 25% 2/8) alive NED Recurr. or prog.: 50% 4/8)
Levin <i>et al.</i> ²⁴⁷	1986	LAVC: N = 6	5-FU 1000 mg/m ² infusion d1-4 + MMC 10 mg/ ² IV d1. 1-2 cycles	20-40 Gy in 2 Gy daily fraction	NA	Mean follow-up: 11 months Status: 66% 4/6) alive NED Recurr.: NA
Koh <i>et al.</i> ²³³	1993	LAVC: N = 4	5-FU 750-1,000 mg/m ² /d for 3-4 d	40-44.8 Gy	CR: 25% 1/4 PR: 50% 2/4)	Mean follow-up: 29.8 months Status: 25% 1/4) alive NED Recurr.: 0% 0/4

^a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, 5-FU: 5-fluorouracil, CisP: cisplatin, CR: complete response, d: days, Gy: Gray, LAVC: locally advanced vulvar cancer, MMC: mitomycin C, NA: not available, NED: no evidence of disease and no recurrence, pCR: pathologic complete response, PR: partial response, prog.: progression, Recurr: recurrence.

Table 11. Original studies included in the meta-analysis published by Stuckey *et al.*²⁴⁹

Author ^{reference}	Year	N	Median age years	Chemotherapy regimen	Radiotherapy regimen	Median follow-up months	DOD %	DOT %	DICD %	NED %
Eifel <i>et al.</i> ²⁴⁵	1995	11	55 37 -85	5-FU/CisP	40-50 Gy	21	27.3	0.0	9.1	63.6
Wahlen <i>et al.</i> ²³⁴	1995	15	64 37 -89	5-FU± MMC	45-50.4 Gy	36	13.3	0.0	13.1	73.3
Berek <i>et al.</i> ²³⁷	1991	12	69 52 -76	5-FU/CisP	46.64 Gy	34	16.7	0.0	0.0	83.3
Whitaker <i>et al.</i> ²⁴⁶	1990	7	73 65 -87	5-FU/MMC	25-50 Gy	7	57.1	14.3	0.0	28.8
Levin <i>et al.</i> ²⁴⁷	1986	5	60 44 -66	5-FU/MMC	18-60 Gy	5	0.0	0.0	0.0	80.0
Beriwal <i>et al.</i> ²⁴⁸	2006	4	66.5 54 -84	5-FU/CisP	43-49 Gy	19.5	0.0	0.0	0.0	100.0
Russel <i>et al.</i> ²²⁹	1992	16	71 13 -90	5-FU ± CisP	46-72 Gy	17 months	6.3%	6.3	0.0	75.0

5-FU: 5-fluorouracil, CisP: cisplatin, DICD: dead of intercurrent disease, DOD: dead of disease, DOT: dead of treatment, Gy: Gray, MMC: mitomycin C, NED: no evidence of disease and no recurrence.

Table 12. Original studies presenting response and survival data in patients treated with adjuvant chemoradiation

Author ^{reference}	Year	N	Chemotherapy regimen	Radiotherapy regimen	Survival
Mak <i>et al.</i> ²³¹	2011	LAVC : N = 10	Either weekly CisP or 3-4 week 5-FU based regimens	50 Gy, timing of fractions varied	Median follow-up: 31.5 months Status: NA Recurr.: NA
Thomas <i>et al.</i> ²³⁰	1989	LAVC: N = 9	5-FU 1,000 mg/m ² infusion d1-4 ± MMC 6 mg/m ² 4/6 one injection, and 2/6 two injections 4 weeks apart	40-64 Gy in 1.6-1.8 Gy twice daily fractions	Median follow-up: 21 months Status: 78% 7/9) alive NED Recurr.: 22% 2/7)
Mulayim <i>et al.</i> ²²⁵	2004	LAVC: N = 6	5-FU 1,000 mg/m ² infusion d1-4 and 21-24 of radiotherapy + MMC 10 mg/m ² IV d1 and d21 of radiotherapy	60 Gy for macro and 45 Gy for microscopic disease	Median follow-up: 20 months Status: 0% 0/6) Recurr.: 33% 2/6)
Han <i>et al.</i> ²³⁶	2000	LAVC: N = 6	5-FU 1,000 mg/m ² infusion d1-4 + MMC 10 mg/m ² IV d1, given week 1 and 5 of radiotherapy	40-62 Gy	Median follow-up: 17 months Status: 83% 5/6) alive NED Recurr.: 17% 1/6)

5-FU: 5-fluorouracil, CisP: cisplatin, Gy: Gray, LAVC: locally advanced vulvar cancer, MMC: mitomycin C, NA: not available, NED: no evidence of disease and no recurrence, Recurr.: recurrence.

13 Systemic treatment

13.1 Summary of available scientific evidence

Neoadjuvant chemotherapy: no studies enrolling at least 50 patients were identified. Results from the 8 identified studies²⁵⁷⁻²⁶⁴ are limited notably by the heterogeneity and the number of patients evaluated only 3 studies^{258,262,263} have accrued in excess of 20 patients, and by the heterogeneity in the chemotherapy regimens. Although studies are very small, agents showing response include bleomycin, cisplatin, and most notably infusional 5-FU **Table 13**. It should be noted that response rates differ quite extensively among the studies. But, the identified trials have not shown significant evidence of improved survival. Additionally, some effective agents produce high toxicity, such as Bleomycin, that is a significant issue.

LoE 3

Adjuvant chemotherapy: only one very small study²⁶⁵ was identified. To assess the use of chemotherapy alone in the adjuvant setting, Bellaty *et al.*²⁶⁵ included 14 patients with inguinal node metastases after radical surgery. Cisplatin 100 mg/m² was administered every 21 days for 4 cycles. Four of 14 patients recurred 29% at a median of 57 months of follow-up, including two recurrences in the groin. Three-year OS and PFS were 86% and 71%, respectively.

LoE 3

Targeted therapy: only one small study was identified. Horowitz *et al.*²⁶⁶ evaluated the efficacy and toxicity of erlotinib 150 mg daily, a selective epidermal growth factor receptor tyrosine kinase inhibitor, among 41 patients with locally advanced, primary, recurrent or metastatic vulvar squamous cell carcinoma. In this first phase II trial, overall clinical benefit rate was 67.5% including partial response 27.5% and stable disease 40%. No complete response has been observed. It should be noted that 1 responses were of relatively short duration and toxicities were significant, and 2 quality of life evaluation was not assessed in this study.

LoE 3

13.2 Previous initiatives

Three previous initiatives^{1,3,39} presenting guidelines on systemic treatment were identified.

13.3 Development group comments

None.

13.4 Guidelines

D

Data in vulvar cancer are insufficient to recommend a preferred schedule in a palliative setting.

Table 13. Original studies presenting data in patients treated with neoadjuvant chemotherapy

Author ^{reference}	Year	N	Chemotherapy regimen	Nb of cycles	Response	Survival
Aragona <i>et al.</i> ²⁶³	2012	LAVC: N = 35	CisP + 5-FU n = 12) or CisP + Tax n = 6 or CisP + 5-FU + Tax n = 6) or VinC + Bleo + CisP n = 6) or Bleo alone n = 5)	3	PR: 86% 30/35)	Median follow-up: 49 months Status: 68% 24/35 alive NED Recurr. : 14% 4/29 of pts undergoing surgery
Domingues <i>et al.</i> ²⁶²	2010	LAVC: N = 25 A N = 10 B N = 5 C N = 10	A Bleo 20 mg/m ² IV d1-10 continuous infusion B Tax 100 mg/m ² IV weekly C 5 -FU 750 mg/m ² d1-4 continuous infusion + CisP 60–80 mg/m ² IV d1, weekly	3	A CR: 10% 1/10, PR: 50% 5/10) B PR: 40% 2/5) C PR : 20% 2/10)	Mean follow-up: 22 months Status: A 30% 3/10 alive NED, B 20% 1/5) alive NED, C 10% 1/10) alive NED Recurr.: NA
Benedetti-Panici <i>et al.</i> ²⁵⁸	1993	LAVC: N = 21	CisP 100 mg/m ² day 1 + Bleo 15 mg days 1 and 8 + MTX 300 mg/m ² day 8 every 21 days	Up to 3	PR in 14% 3/21) SD in 81% 17/21)	Median follow-up: 33 months Status : NA Recurr. : NA
Durrant <i>et al.</i> ²⁵⁷	1990	LAVC: N = 18	Bleo 5 mg IM d1–5 + MTX 15 mg PO d1 and 4 + CCNU 40 mg PO d5-7 week 1, then Bleo 5 mg IM d1 and 4 + MTX 15 mg PO d1 and 4 weeks 2-5	Up to 4	ORR: 67% 12/18)	Follow-up: NA Status: NA Recurr.: NA
Geisler <i>et al.</i> ²⁶¹	2006	LAVC: N = 13 A N = 10 B N = 3	A 5 -FU 1,000 mg/m ² /24 h infusion d1-5 + CisP 50 mg/m ² IV d1, q3 weeks B CisP 50 mg/m ² IV q3 weeks	3-4	A PR: 60% 6/10), pCR: 40% 4/10) B 0% response	Median follow-up: 49 months Status: A 90% 9/10 alive NED, B 0% alive NED Recurr.: NA
Wagenaar <i>et al.</i> ²⁵⁹	2001	LAVC: N = 12	Week 1: Bleo 5 mg IM d1-5 + CCNU 40 mg PO d5-7 + MTX 10 mg PO d1+4 Weeks 2-6: Bleo 5 mg IM d1 + 4 + MTX 15 mg PO d1.	Up to 3	ORR: 58% 7/12	Median follow-up: 8 months Status: NA Recurr.: NA
Bafna <i>et al.</i> ²⁶⁰	2004	LAVC: N = 9	Cyclo 500 mg + MTX 50 mg + 5-FU 500 mg days 1, 8 every 14 d	3	pCR: 11% 1/9 PR: 89% 8/9)	Follow-up: NA Status: NA Recurr.: NA
Han <i>et al.</i> ²⁶⁴	2012	LAVC: N = 4	Tax 60 mg/m ² IV + Carbo AUC 2.7 IV weekly	Up to 9	ORR = 0%	Mean follow-up: 12 months Status: 50% 2/4) alive NED Recurr. : -

5-FU: 5-fluorouracil, Bleo: bleomycin, Carbo: carboplatin, CisP: cisplatin, CCNU: lomustine, CR: complete response, Cyclo: cyclophosphamide, LAVC: locally-advanced vulvar cancer, MTX: methotrexate, NA: not available, NED: no evidence of disease and no recurrence, ORR: overall response rate, pCR: pathologic complete response, PR: partial response, Recurr. : recurrence, Tax: paclitaxel, VinC: vincristine.

14 Treatment of recurrent disease

14.1 Summary of available scientific evidence

Chemoradiation: no studies enrolling at least 50 patients were identified. Results from the 8 identified studies^{227-230,241,244,251,252} are limited notably by the small number of patients evaluated only one study²⁵¹ has accrued in excess of 20 patients and by the heterogeneity in the chemoradiation regimens **Table 14.** **LoE 3**

Chemotherapy: no studies enrolling at least 50 patients were identified. Results from the 7 identified trials^{257,259,264,267-270} are limited notably by the small number of patients evaluated only 2 trials^{267,268} have accrued in excess of 20 patients and by the heterogeneity in the chemotherapy regimens **Table 15.** **LoE 3**

14.2 Previous initiatives

Four previous initiatives^{1-3,39} presenting guidelines on treatment of recurrent disease were identified.

14.3 Development group comments

Local recurrences should be treated as primary tumours with wide local excision and inguinofemoral lymphadenectomy in case of depth of invasion >1 mm and not performed previously.

CT thorax/abdomen or PET/CT thorax/abdomen is recommended to examine the presence of additional metastases, which presence may influence treatment planning. Imaging might also be helpful in determining the possibility of surgical resection.

14.4 Guidelines

Treatment of vulvar recurrence

- ✓ Radical local excision is recommended.
- ✓ For vulvar recurrence with a depth of invasion > 1 mm and previous sentinel lymph node removal only, inguinofemoral lymphadenectomy should be performed.
- ✓ The indications for postoperative radiotherapy are comparable to those for the treatment of primary disease.

Treatment of groin recurrence

- ✓ Restaging by CT or PET -CT of the thorax/abdomen/pelvis is recommended.
- ✓ Preferred treatment is radical excision when possible, followed by postoperative radiation in radiotherapy naïve patients.
- ✓ Based on evidence from other squamous cell cancers such as cervical and anal cancer, the addition of radiosensitising chemotherapy to postoperative radiotherapy should be considered.
- ✓ Definitive chemoradiation when surgical treatment is not possible.

Treatment of distant metastases

- ✓ Systemic palliative therapy may be considered in individual patients (see systemic treatment).

Table 14. Original studies presenting response and survival data in recurrent patients treated with chemoradiation

Author ^{reference}	Year		Chemotherapy regimen	Radiotherapy regimen	Response	Survival
Scheistroen <i>et al.</i> ²⁵¹	1993	22	Bleo 30 mg IV d1, 3, 5 during weeks 1 + 3 of radiotherapy	30-45 Gy in 3 Gy daily fractions	CR: 9% 2/22 PR: 50% 11/22)	Follow-up: NA Status: NA Recurr.: NA
Landoni <i>et al.</i> ^{a,244}	1996	17	5-FU 750 mg/m ² infusion d1-5 + MMC 15 mg/m ² IV d1 given week 1 of each course of radiotherapy	54 Gy in 2 courses 3 6 Gy + 18 Gy) with 14 d treatment break	pCR: 18% 3/17 pPR: 35% 6/17)	Follow-up: NA Status: 29% 5/17 alive NED Recurr.: NA
Sebag-Montefiore <i>et al.</i> ²²⁷	1994	16	5-FU 750 mg/m ² infusion d1-5 + MMC 10 mg/m ² IV d1, given first 5 d and last 5 d of radiotherapy	45 Gy in 2-2.5 Gy daily fractions	CR : 50% 8/16) PR : 31% 5/16	Follow-up: NA Status: NA Recurr.: NA
Thomas <i>et al.</i> ²³⁰	1989	15	5-FU 1,000 mg/m ² infusion d1-4 ± MMC 6 mg/m ² 4/6 one injection, and 2/6 two injections 4 weeks apart	40-64 Gy in 1.6-1.8 Gy twice daily fractions	CR: 53% 8/15	Follow-up: 5-45 months Status: 47% 7/15 alive NED Recurr.: NA
Tans <i>et al.</i> ²²⁸	2011	8	5-FU 1,000 mg/m ² infusion d1-4 + MMC 10 mg/m ² IV d1, given first week of each course of radiotherpay	Split course 40 Gy + 20 Gy in 2 Gy fractions with 2-week break	CR: 75% 6/8	Median follow-up: NA Status: NA Recurr.: NA
Russel <i>et al.</i> ²²⁹	1992	7	5-FU 750-1,000 mg/m ² infusion d1-4 + CisP 100 mg/m ² IV d1, 2-3 cycles given	54 Gy for macro and 36 Gy for microscopic disease	CR: 57% 4/7	Mean follow-up: 17.9 months Status: 29% 2/7) alive NED Recurr.: 14% 1/7) in pts with pCR
Lupi <i>et al.</i> ^{a,252}	1996	7	5-FU 750 mg/m ² infusion d1-5 + MMC 15 mg/m ² IV d1, given for 2 cycles	54 Gy in 2 courses with 14 d treatment break	CR: 71% 5/7 PR: 29% 2/7)	Median follow-up: 38 months Status: 57% 4 /7) alive NED Recurr.: NA
Kalra <i>et al.</i> ^{a,241}	1985	1	MMC 10 mg/m ² IV d1 + 5-FU 1000mg/m ² infusion d1-5, given weeks 1 and 4 of radiotherapy	50 Gy in 2 Gy daily fractions	CR: 100% 1/1	Follow-up: NA Status: 100% 1/1 alive NED Recurr. : 0% 0/1)

^a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, 5-FU: 5-fluorouracil, Bleo: bleomycin, CR: complete response, CisP: cisplatin, Gy: Gray, MMC: mitomycin C, NA: not available, NED: no evidence of disease and no recurrence, pCR: pathologic complete response, pPR pathologic partial response, PR: partial response, Recurr. recurrence.

Table 15. Original studies presenting data in recurrent patients treated with chemotherapy alone

Author ^{reference}	Year	N	Chemotherapy regimen	Response	Survival
Witteveen <i>et al.</i> ²⁶⁷	2009	29	Tax 175 mg/m ² IV q3 weeks; up to 9 cycles	ORR: 13.8% 4/29 CR: 6% 2/29 PR: 6% 2/29)	Median PFS: 2.6 months Median OS: 6.8 months
Thigpen <i>et al.</i> ²⁶⁸	1986	22	CisP 50 mg/m ² IV q3 weeks	ORR: 0% CR: 0% PR: 0%	NA
Cormio <i>et al.</i> ²⁶⁹	2009	15	CisP 80 mg/m ² IV d1 + Vinorelbine 25 mg/m ² IV d1 and d8, q21 d for up to 6 cycles	ORR: 40% 6/15 CR: 27% 4/15 PR: 13% 2/15	Median PFS: 10 months Median OS: 19 months
Thigpen <i>et al.</i> ²⁶⁸	1986	13	Piperazinedione 9 mg/m ² IV q3 weeks	ORR: 0% CR: 0% PR: 0%	PFS: NA OS: NA
Wagenaar <i>et al.</i> ²⁵⁹	2001	13	Week 1: Bleo 5 mg IM d1-5 + CCNU 40 mg PO d5-7 + MTX 10 mg PO d1+4 Weeks 2-6: Bleo 5 mg IM d1 + 4 + MTX 15 mg PO d1.	ORR: 54% 7/13	Median follow-up: 8 months Median PFS: 4.8 months ^a Median OS: 7.8 months ^a
Muss <i>et al.</i> ²⁷⁰	1989	11	Mitoxantrone 12 mg/m ² IV q3 weeks	ORR: 0% CR: 0% PR: 0%	Median PFS: 1.3 months Median OS: 3.2 months
Durrant <i>et al.</i> ²⁵⁷	1990	11	Bleo 5 mg IM d1-5 + MTX 15 mg PO d1 and 4 + CCNU 40 mg PO d5-7 week 1, then Bleo 5 mg IM d1 and 4 + MTX 15 mg PO d1 and 4 weeks 2-5	ORR: 60% 6/ 10 CR : NA PR : NA	PFS: NA OS: NA
Han <i>et al.</i> ²⁶⁴	2012	2	Tax 60 mg/m ² IV + Carbo AUC 2.7 IV weekly	ORR = 0%	Mean follow-up: 3.5 months PFS: - OS: NA

^a median survival among 12 patients with primary locally advanced disease and 13 with locoregional recurrence data not available for patients with locoregional recurrence specifically), Bleo bleomycin, Carbo: carboplatin, CCNU: lomustine, CisP: cisplatin, CR: complete response, LAVC: locally advanced vulvar cancer, NA: not available, ORR: overall response rate, OS: overall survival, PR: partial response, PFS: progression-free survival, MTX: methotrexate, Tax: paclitaxel.

15 Follow-up

15.1 Summary of available scientific evidence

No directly applicable clinical studies have been identified.

15.2 Previous initiatives

Six previous initiatives^{1-3,38,39,271} presenting guidelines on follow-up were identified.

15.3 Development group comments

There is no evidence for best follow-up schedule. Since local recurrences may occur many years after primary treatment, lifelong follow-up is advised.

Since patients with associated vulvar intraepithelial neoplasia or lichen sclerosus/planus have a higher risk on local recurrence, more intensive follow-up may be indicated.

15.4 Guidelines



The optimal follow-up schedule for vulvar cancer is undetermined.



After primary surgical treatment the following follow-up schedule is suggested:

- First follow-up 6-8 weeks postoperative
- First two years every three-four months
- Third and fourth year biannually
- Afterward, long-term follow-up, especially in case of predisposing vulvar disease.

Follow-up after surgical treatment should include clinical examination of vulva and groins.⁴



After definitive chemoradiation the following follow-up schedule is suggested:

- First follow-up visit 10-12 weeks post completion of definitive chemoradiation.
- First two years every three-four months
- Third and fourth year biannually
- Afterward, long-term follow-up, especially in case of predisposing vulvar disease.

At first follow-up visit 10-12 weeks post definitive chemoradiation CT or PET-CT is recommended to document complete remission.

⁴ Despite the well-recognized low sensitivity of palpation to identify groin recurrences, currently available data do not support routine use of imaging of the groins in follow-up.

16 Acronyms and abbreviations

5-FU 5-fluorouracil

99mTc technetium-99m

ACPG Alberta clinical practice guidelines

AGDH Australian government department of health

AHRQ agency for healthcare research and quality

AquAS agència de qualitat i avaluació sanitàries de Catalunya

ASCO American society of clinical oncology

AUC area under the curve

BCCA British Columbia cancer agency

BID twice a day

Bleo bleomycin

CADTH Canadian agency for drugs and technologies in health

Carbo carboplatin

CCO cancer care Ontario

CCNU lomustine

cCR clinical complete response

CEPO comité de l'évolution des pratiques en oncologie

CI confidence interval

CisP cisplatin

CoCanCPG coordination of cancer clinical practice guidelines in Europe

COMPAQ-HPST coordination pour la mesure de la performance et l'amélioration de la qualité, hôpital, patient, sécurité, territoire

CR complete response

CT computed tomography

Cyclo cyclophosphamide

DICD dead of intercurrent disease

DOD dead of disease

DOT dead of treatment

DSS disease specific survival

ECOG Eastern cooperative oncology group

ESGO European society of gynaecological oncology

ESMO European society of medical Oncology

FIGO international federation of gynecology and obstetrics

FN false negative

FNA fine-needle aspiration

FNAC fine-needle aspiration cytology

FP false positive

GIN guidelines international network

GOC gynaecological oncology centre

GOG gynecologic oncology group

GROINSS-V Groningen international study on sentinel nodes in vulvar cancer

H&E haematoxylin and eosin

HAS haute autorité de santé

HR hazard ratio

IHC immunohistochemistry

ILND inguinal lymph node dissection

IMRT intensity-modulated radiation therapy

INAHTA international network of agencies for health technology assessment

INCa institut national du cancer

INESSS institut national d'excellence en santé et en services sociaux

IPTW inverse probability of treatment weighting

KCE centre fédéral d'expertise des soins de santé

LAVC locally advanced vulvar cancer

MMC mitomycin C	PET positron emission tomography
MRI magnetic resonance imaging	PET-CT positron emission tomography-computed tomography
MSAC medical services advisory committee	PFS progression-free survival
MTX methotrexate	PR partial response
NA not available	Recurr recurrence
NCCN national comprehensive cancer network	RCT randomised controlled trial
NED no evidence of disease and no recurrence	SIGN Scottish intercollegiate guidelines network
NHMRC national health and medical research council	SLN sentinel lymph node
NHS national health service	Tax paclitaxel
NICE national institute for health and care excellence	TN true negative
NZGG New Zealand guidelines group	TP true positive
OR odd ratio	UICC union internationale contre le cancer
ORR overall response rate	VinC vincristine
OS overall survival	
pCR pathologic complete response	

17 References

1. NHS. Medical Protocol - Oncological Management of Vulvar Cancer http://www.cmscsenate.nhs.uk/index.php/download_file/view/415/1178/ 2015.
2. UHN. Princess Margaret Cancer Centre - Clinical Practice Guidelines - Gynecologic Cancer. http://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Gynecologic/Pages/clinical_practice_guidelines.aspx 2015.
3. RCOG. Guidelines for the Diagnosis and Management of Vulval Carcinoma. <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/vulval-carcinoma-guidelines-for-the-diagnosis-and-management-of/> 2014.
4. GMCT. Gynaecological Cancer Guidelines. http://www.aci.health.nsw.gov.au/_data/assets/pdf_file/0010/154549/go_clinical_guidelines.pdf 2009.
5. Sobin, L.H., Gospodarowicz, M.K. & Wittekind, C.H. TNM classification of malignant tumours. 7th edition. Oxford: Wiley-Blackwell 2009.
6. Pecorelli, S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* **105**, 103-104 2009.
7. Petru, E., *et al.* Gynecologic Cancer Intergroup (GIG) proposals for changes of the current FIGO staging system. *Eur J Obstet Gynecol Reprod Biol* **143**, 69-74 2009.
8. Wilkinson, E.J., Rico, M.J. & Pierson, K.K. Microinvasive carcinoma of the vulva. *Int J Gynecol Pathol* **1**, 29-39 1982.
9. van der Steen, S., de Nieuwenhof, H.P., Massuger, L., Bulten, J. & de Hullu, J.A. New FIGO staging system of vulvar cancer indeed provides a better reflection of prognosis. *Gynecol Oncol* **119**, 520-525 2010.
10. Tabbaa, Z.M., *et al.* Impact of the new FIGO 2009 staging classification for vulvar cancer on prognosis and stage distribution. *Gynecol Oncol* **127**, 147-152 2012.
11. Tan, J., *et al.* Validation of the FIGO 2009 staging system for carcinoma of the vulva. *Int J Gynecol Cancer* **22**, 498-502 2012.
12. Beugeling, M., Ewing-Graham, P.C., Mzallassi, Z. & van Doorn, H.C. Pathology slide review in vulvar cancer does not change patient management. *ISRN Surg* **2014**, 385386 2014.
13. Santoso, J.T., *et al.* Pathology slide review in gynecologic oncology. *Obstet Gynecol* **91**, 730-734 1998.
14. Chafe, S., Honore, L., Pearcey, R. & Capstick, V. An analysis of the impact of pathology review in gynecologic cancer. *Int J Radiat Oncol Biol Phys* **48**, 1433-1438 2000.
15. Khalifa, M.A., Dodge, J., Covens, A., Osborne, R. & Ackerman, I. Slide review in gynecologic oncology ensures completeness of reporting and diagnostic accuracy. *Gynecol Oncol* **90**, 425-430 2003.
16. Selman, A.E., Niemann, T.H., Fowler, J.M. & Copeland, L.J. Quality assurance of second opinion pathology in gynecologic oncology. *Obstet Gynecol* **94**, 302-306 1999.
17. Chan, Y.M., *et al.* Pathology slide review in gynecologic oncology: routine or selective? *Gynecol Oncol* **75**, 267-271 1999.
18. Iversen, T. The value of groin palpation in epidermoid carcinoma of the vulva. *Gynecol Oncol* **12**, 291-295 1981.
19. Piura, B., Rabinovich, A., Cohen, Y., Friger, M. & Glezerman, M. Squamous cell carcinoma of the vulva in the south of Israel: a study of 50 cases. *J Surg Oncol* **67**, 174-181 1998.

20. Singh, K., *et al.* Accuracy of magnetic resonance imaging of inguinofemoral lymph nodes in vulval cancer. *Int J Gynecol Cancer* **16**, 1179-1183 2006.
21. Podratz, K.C., Symmonds, R.E., Taylor, W.F. & Williams, T.J. Carcinoma of the vulva: analysis of treatment and survival. *Obstet Gynecol* **61**, 63-74 1983.
22. Selman, T.J., Luesley, D.M., Acheson, N., Khan, K.S. & Mann, C.H. A systematic review of the accuracy of diagnostic tests for inguinal lymph node status in vulvar cancer. *Gynecol Oncol* **99**, 206-214 2005.
23. Hawnaur, J.M., Reynolds, K., Wilson, G., Hillier, V. & Kitchener, H.C. Identification of inguinal lymph node metastases from vulval carcinoma by magnetic resonance imaging: an initial report. *Clin Radiol* **57**, 995-1000 2002.
24. Sohaib, S.A., *et al.* MR imaging of carcinoma of the vulva. *AJR Am J Roentgenol* **178**, 373-377 2002.
25. Bipat, S., *et al.* Is there a role for magnetic resonance imaging in the evaluation of inguinal lymph node metastases in patients with vulva carcinoma? *Gynecol Oncol* **103**, 1001-1006 2006.
26. Kataoka, M.Y., *et al.* The accuracy of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-centre study. *Gynecol Oncol* **117**, 82-87 2010.
27. Cohn, D.E., *et al.* Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. *Gynecol Oncol* **85**, 179-184 2002.
28. De Hullu, J.A., *et al.* Noninvasive detection of inguinofemoral lymph node metastases in squamous cell cancer of the vulva by L. *Int J Gynecol Cancer* **9**, 141-146 1999.
29. Kamran, M.W., *et al.* Whole-body [18F]fluoro-2-deoxyglucose positron emission tomography scan as combined PET-CT staging prior to planned radical vulvectomy and inguinofemoral lymphadenectomy for squamous vulvar cancer: a correlation with groin node metastasis. *Eur J Gynaecol Oncol* **35**, 230-235 2014.
30. Moskovic, E.C., *et al.* The role of high resolution ultrasound with guided cytology of groin lymph nodes in the management of squamous cell carcinoma of the vulva: a pilot study. *Br J Obstet Gynaecol* **106**, 863-867 1999.
31. Hall, T.B., *et al.* The role of ultrasound-guided cytology of groin lymph nodes in the management of squamous cell carcinoma of the vulva: 5-year experience in 44 patients. *Clin Radiol* **58**, 367-371 2003.
32. Makela, P.J., Leminen, A., Kaariainen, M. & Lehtovirta, P. Pretreatment sonographic evaluation of inguinal lymph nodes in patients with vulvar malignancy. *J Ultrasound Med* **12**, 255-258 1993.
33. Abang Mohammed, D.K., Uberoi, R., de, B.L.A. & Monaghan, J.M. Inguinal node status by ultrasound in vulva cancer. *Gynecol Oncol* **77**, 93-96 2000.
34. de Gregorio, N., *et al.* The role of preoperative ultrasound evaluation of inguinal lymph nodes in patients with vulvar malignancy. *Gynecol Oncol* **131**, 113-117 2013.
35. McCall, A.R., Olson, M.C. & Potkul, R.K. The variation of inguinal lymph node depth in adult women and its importance in planning elective irradiation for vulvar cancer. *Cancer* **75**, 2286-2288 1995.
36. Koh, W.J., *et al.* Femoral vessel depth and the implications for groin node radiation. *Int J Radiat Oncol Biol Phys* **27**, 969-974 1993.
37. Kidd, E., *et al.* ACR Appropriateness CriteriaR management of locoregionally advanced squamous cell carcinoma of the vulva. *Am J Clin Oncol* **36**, 415-422 2013.

38. AHS. Squamous Cell Carcinoma of the Vulva.
<http://www.albertahealthservices.ca/hp/if-hp-cancer-guide-gyne006-vulva.pdf> 2013.
39. NCCN. Vulvar Cancer Squamous Cell Carcinoma. Version 1.
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp 2016.
40. Farias-Eisner, R., *et al.* Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II T1 -2N0-1M0 disease. *Gynecol Oncol* **53**, 55-58 1994.
41. Balat, O., Edwards, C. & Delclos, L. Complications following combined surgery radical vulvectomy versus wide local excision and radiotherapy for the treatment of carcinoma of the vulva: report of 73 patients. *Eur J Gynaecol Oncol* **21**, 501-503 2000.
42. De Hullu, J.A., *et al.* Vulvar carcinoma. The price of less radical surgery. *Cancer* **95**, 2331-2338 2002.
43. Rutledge, F.N., *et al.* Prognostic indicators for invasive carcinoma of the vulva. *Gynecol Oncol* **42**, 239-244 1991.
44. DeSimone, C.P., *et al.* The treatment of lateral T1 and T2 squamous cell carcinomas of the vulva confined to the labium majus or minus. *Gynecol Oncol* **104**, 390-395 2007.
45. van der Velden, J. Surgical interventions for early squamous cell carcinoma of the vulva. *Cochrane Database Syst Rev*, CD002036 2000.
46. Burke, T.W., *et al.* Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. *Gynecol Oncol* **57**, 215-220 1995.
47. DiSaia, P.J., Creasman, W.T. & Rich, W.M. An alternate approach to early cancer of the vulva. *Am J Obstet Gynecol* **133**, 825-832 1979.
48. Heaps, J.M., Fu, Y.S., Montz, F.J., Hacker, N.F. & Berek, J.S. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. *Gynecol Oncol* **38**, 309-314 1990.
49. Tantipalakorn, C., Robertson, G., Marsden, D.E., Gebiski, V. & Hacker, N.F. Outcome and patterns of recurrence for International Federation of Gynecology and Obstetrics (FIGO) stages I and II squamous cell vulvar cancer. *Obstet Gynecol* **113**, 895-901 2009.
50. Berman, M.L., Soper, J.T., Creasman, W.T., Olt, G.T. & DiSaia, P.J. Conservative surgical management of superficially invasive stage I vulvar carcinoma. *Gynecol Oncol* **35**, 352-357 1989.
51. Gunther, V., *et al.* Impact of radical operative treatment on the quality of life in women with vulvar cancer--a retrospective study. *Eur J Surg Oncol* **40**, 875-882 2014.
52. Curry, S.L., Wharton, J.T. & Rutledge, F. Positive lymph nodes in vulvar squamous carcinoma. *Gynecol Oncol* **9**, 63-67 1980.
53. Hacker, N.F., Berek, J.S., Lagasse, L.D., Leuchter, R.S. & Moore, J.G. Management of regional lymph nodes and their prognostic influence in vulvar cancer. *Obstet Gynecol* **61**, 408-412 1983.
54. Hacker, N.F., Berek, J.S., Lagasse, L.D., Nieberg, R.K. & Leuchter, R.S. Individualization of treatment for stage I squamous cell vulvar carcinoma. *Obstet Gynecol* **63**, 155-162 1984.
55. Hoffman, J.S., Kumar, N.B. & Morley, G.W. Microinvasive squamous carcinoma of the vulva: search for a definition. *Obstet Gynecol* **61**, 615-618 1983.
56. Ross, M.J. & Ehrmann, R.L. Histologic prognosticators in stage I squamous cell carcinoma of the vulva. *Obstet Gynecol* **70**, 774-784 1987.

57. Iversen, T., Abeler, V. & Aalders, J. Individualized treatment of stage I carcinoma of the vulva. *Obstet Gynecol* **57**, 85-89 1981.
58. Kelley, J.L., 3rd, *et al.* Minimally invasive vulvar carcinoma: an indication for conservative surgical therapy. *Gynecol Oncol* **44**, 240-244 1992.
59. Magrina, J.F., *et al.* Squamous cell carcinoma of the vulva stage IA: long-term results. *Gynecol Oncol* **76**, 24-27 2000.
60. Van Der Velden, J., Kooyman, C.D., Van Lindert, A.C. & Heintz, A.P. A stage Ia vulvar carcinoma with an inguinal lymph node recurrence after local excision. A case report and literature review. *Int J Gynecol Cancer* **2**, 157-159 1992.
61. Sidor, J., Diallo-Danebrock, R., Eltze, E. & Lelle, R.J. Challenging the concept of microinvasive carcinoma of the vulva: report of a case with regional lymph node recurrence and review of the literature. *BMC Cancer* **6**, 157 2006.
62. Volgger, B., *et al.* Fulminant course of a microinvasive vulvar carcinoma in an immunosuppressed woman. *Gynecol Oncol* **65**, 177-179 1997.
63. Thangavelu, A., Andrew, A. & Buxton, E.J. Groin recurrence following Stage 1A squamous cell carcinoma of the vulva. *Gynecol Oncol* **101**, 172-174 2006.
64. Atamdede, F. & Hoogerland, D. Regional lymph node recurrence following local excision for microinvasive vulvar carcinoma. *Gynecol Oncol* **34**, 125-128 1989.
65. Hicks, M.L., Hempling, R.E. & Piver, M.S. Vulvar carcinoma with 0.5 mm of invasion and associated inguinal lymph node metastasis. *J Surg Oncol* **54**, 271-273 1993.
66. Stehman, F.B., Bundy, B.N., Dvoretzky, P.M. & Creasman, W.T. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. *Obstet Gynecol* **79**, 490-497 1992.
67. Gordinier, M.E., *et al.* Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy. *Gynecol Oncol* **90**, 625-628 2003.
68. Kirby, T.O., *et al.* Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. *Gynecol Oncol* **98**, 309-312 2005.
69. Andrews, S.J., *et al.* Therapeutic implications of lymph nodal spread in lateral T1 and T2 squamous cell carcinoma of the vulva. *Gynecol Oncol* **55**, 41-46 1994.
70. Tham, K.F., Shepherd, J.H., Lowe, D.G., Hudson, C.N. & Van Dam, P.A. Early vulval cancer: the place of conservative management. *Eur J Surg Oncol* **19**, 361-367 1993.
71. Jackson, K.S., Das, N., Naik, R., Lopes, A. & Monaghan, J.M. Contralateral groin node metastasis following ipsilateral groin node dissection in vulval cancer: a case report. *Gynecol Oncol* **89**, 529-531 2003.
72. Van der Velden, J. Some aspects of the management of squamous cell carcinoma of the vulva. *Thesis. Amsterdam, The Netherlands* 1996.
73. Zhang, S.H., Sood, A.K., Sorosky, J.I., Anderson, B. & Buller, R.E. Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva. *Cancer* **89**, 1520-1525 2000.
74. Zhang, X., *et al.* Sparing of saphenous vein during inguinal lymphadenectomy for vulval malignancies. *Gynecol Oncol* **105**, 722-726 2007.
75. Rouzier, R., Haddad, B., Dubernard, G., Dubois, P. & Paniel, B.J. Inguinofemoral dissection for carcinoma of the vulva: effect of modifications of extent and

- technique on morbidity and survival. *J Am Coll Surg* **196**, 442-450 2003.
76. Dardarian, T.S., Gray, H.J., Morgan, M.A., Rubin, S.C. & Randall, T.C. Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. *Gynecol Oncol* **101**, 140-142 2006.
 77. Paley, P.J., *et al.* The effect of sartorius transposition on wound morbidity following inguinal-femoral lymphadenectomy. *Gynecol Oncol* **64**, 237-241 1997.
 78. Lin, J.Y., DuBeshter, B., Angel, C. & Dvoretzky, P.M. Morbidity and recurrence with modifications of radical vulvectomy and groin dissection. *Gynecol Oncol* **47**, 80-86 1992.
 79. Soliman, A.A., Heubner, M., Kimmig, R. & Wimberger, P. Morbidity of inguinofemoral lymphadenectomy in vulvar cancer. *ScientificWorldJournal* **2012**, 341253 2012.
 80. Fotiou, S.K., *et al.* "Butterfly" operation vs triple incision technique in vulvar cancer. a comparison of morbidity and clinical outcome. *Eur J Gynaecol Oncol* **17**, 67-73 1996.
 81. van der Velden, J., Schilthuis, M.S., Hyde, S.E., Ten Kate, F.J. & Burger, M.P. Squamous cell cancer of the vulva with occult lymph node metastases in the groin: the impact of surgical technique on recurrence pattern and survival. *Int J Gynecol Cancer* **14**, 633-638 2004.
 82. Helm, C.W., *et al.* A matched comparison of single and triple incision techniques for the surgical treatment of carcinoma of the vulva. *Gynecol Oncol* **46**, 150-156 1992.
 83. Siller, B.S., *et al.* T2/3 vulva cancer: a case-control study of triple incision versus en bloc radical vulvectomy and inguinal lymphadenectomy. *Gynecol Oncol* **57**, 335-339 1995.
 84. Hacker, N.F., Leuchter, R.S., Berek, J.S., Castaldo, T.W. & Lagasse, L.D. Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions. *Obstet Gynecol* **58**, 574-579 1981.
 85. Grimshaw, R.N., Murdoch, J.B. & Monaghan, J.M. Radical vulvectomy and bilateral inguinal-femoral lymphadenectomy through separate incisions-experience with 100 cases. *Int J Gynecol Cancer* **3**, 18-23 1993.
 86. Fambrini, M., *et al.* Two-team simultaneous total radical vulvectomy and inguino-femoral lymphadenectomy via separate incisions for locally advanced FIGO stages IB >= 4 cm -III squamous vulvar cancer. *Anticancer Res* **34**, 7345-7350 2014.
 87. SOGC. Management of Squamous Cell Cancer of the Vulva. <http://sogc.org/fr/guidelines/prise-en-charge-du-cancer-spinocellulaire-de-la-vulve-remplace-2-mai-1993/> 2006.
 88. CCO. Sentinel Lymph Node Biopsy in Vulvar Cancer. <https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=313084> 2014.
 89. Hassanzade, M., Attaran, M., Treglia, G., Yousefi, Z. & Sadeghi, R. Lymphatic mapping and sentinel node biopsy in squamous cell carcinoma of the vulva: systematic review and meta-analysis of the literature. *Gynecol Oncol* **130**, 237-245 2013.
 90. Meads, C., *et al.* Sentinel lymph node biopsy in vulvar cancer: systematic review and meta-analysis. *Br J Cancer* **110**, 2837-2846 2014.
 91. Lawrie, T.A., *et al.* Sentinel node assessment for diagnosis of groin lymph node involvement in vulvar cancer. *Cochrane Database Syst Rev* **6**, CD010409 2014.
 92. Levenback, C., *et al.* Intraoperative lymphatic mapping for vulvar cancer. *Obstet Gynecol* **84**, 163-167 1994.

93. Decesare, S.L., *et al.* A pilot study utilizing intraoperative lymphoscintigraphy for identification of the sentinel lymph nodes in vulvar cancer. *Gynecol Oncol* **66**, 425-428 1997.
94. Bowles, J., Terada, K.Y., Coel, M.N. & Wong, J.H. Preoperative lymphoscintigraphy in the evaluation of squamous cell cancer of the vulva. *Clin Nucl Med* **24**, 235-238 1999.
95. Ansink, A.C., *et al.* Identification of sentinel lymph nodes in vulvar carcinoma patients with the aid of a patent blue V injection: a multicenter study. *Cancer* **86**, 652-656 1999.
96. Rodier, J.F., *et al.* Sentinel node biopsy in vulvar malignancies: a preliminary feasibility study. *Oncol Rep* **6**, 1249-1252 1999.
97. De Cicco, C., *et al.* Sentinel node biopsy in early vulvar cancer. *Br J Cancer* **82**, 295-299 2000.
98. de Hullu, J.A., *et al.* Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. *J Clin Oncol* **18**, 2811-2816 2000.
99. Sideri, M., *et al.* Detection of sentinel nodes by lymphoscintigraphy and gamma probe guided surgery in vulvar neoplasia. *Tumori* **86**, 359-363 2000.
100. Tavares, M.G., *et al.* The use of 99mTc-phytate for sentinel node mapping in melanoma, breast cancer and vulvar cancer: a study of 100 cases. *Eur J Nucl Med* **28**, 1597-1604 2001.
101. Trope, C., *et al.* [Surgery and sentinel node examination in early vulvar cancer]. *Tidsskr Nor Laegeforen* **121**, 2723-2727 2001.
102. Molpus, K.L., Kelley, M.C., Johnson, J.E., Martin, W.H. & Jones, H.W., 3rd. Sentinel lymph node detection and microstaging in vulvar carcinoma. *J Reprod Med* **46**, 863-869 2001.
103. Sliutz, G., *et al.* Lymphatic mapping of sentinel nodes in early vulvar cancer. *Gynecol Oncol* **84**, 449-452 2002.
104. Zambo, K., *et al.* Preliminary experiences with sentinel lymph node detection in cases of vulvar malignancy. *Eur J Nucl Med Mol Imaging* **29**, 1198-1200 2002.
105. Radziszewski, J., *et al.* Sentinel lymph node in vulvar cancer-a pilot study to identify and assess the diagnostic value. *NOWOTWORY* **53**, 268-274 2003.
106. Moore, R.G., Granai, C.O., Gajewski, W., Gordinier, M. & Steinhoff, M.M. Pathologic evaluation of inguinal sentinel lymph nodes in vulvar cancer patients: a comparison of immunohistochemical staining versus ultrastaging with hematoxylin and eosin staining. *Gynecol Oncol* **91**, 378-382 2003.
107. Boran, N., Kayikcioglu, F. & Kir, M. Sentinel lymph node procedure in early vulvar cancer. *Gynecol Oncol* **90**, 492-493 2003.
108. Hakam, A., *et al.* Value of multilevel sectioning for improved detection of micrometastases in sentinel lymph nodes in invasive squamous cell carcinoma of the vulva. *Anticancer Res* **24**, 1281-1286 2004.
109. Basta, A., *et al.* Sentinel node in gynaecological oncology. *Rep Prac Oncol Radiother* **10**, 91-94 2005.
110. Merisio, C., *et al.* Radioguided sentinel lymph node detection in vulvar cancer. *Int J Gynecol Cancer* **15**, 493-497 2005.
111. Carcopino, X., *et al.* [Feasibility and morbidity of sentinel lymph node detection in patients with vulvar carcinoma]. *Bull Cancer* **92**, 489-497 2005.
112. Louis-Sylvestre, C., *et al.* [Interpretation of sentinel node identification in vulvar cancer]. *Gynecol Obstet Fertil* **34**, 706-710 2006.
113. Terada, K.Y., Shimizu, D.M., Jiang, C.S. & Wong, J.H. Outcomes for patients with

- T1 squamous cell cancer of the vulva undergoing sentinel node biopsy. *Gynecol Oncol* **102**, 200-203 2006.
114. Vidal-Sicart, S., *et al.* Validation and application of the sentinel lymph node concept in malignant vulvar tumours. *Eur J Nucl Med Mol Imaging* **34**, 384-391 2007.
 115. Rob, L., *et al.* Further data on sentinel lymph node mapping in vulvar cancer by blue dye and radiocolloid Tc99. *Int J Gynecol Cancer* **17**, 147-153 2007.
 116. Nyberg, R.H., Iivonen, M., Parkkinen, J., Kuoppala, T. & Maenpaa, J.U. Sentinel node and vulvar cancer: a series of 47 patients. *Acta Obstet Gynecol Scand* **86**, 615-619 2007.
 117. Johann, S., Klaeser, B., Krause, T. & Mueller, M.D. Comparison of outcome and recurrence-free survival after sentinel lymph node biopsy and lymphadenectomy in vulvar cancer. *Gynecol Oncol* **110**, 324-328 2008.
 118. Hampl, M., Hantschmann, P., Michels, W. & Hillemanns, P. Validation of the accuracy of the sentinel lymph node procedure in patients with vulvar cancer: results of a multicenter study in Germany. *Gynecol Oncol* **111**, 282-288 2008.
 119. Klat, J., *et al.* Characteristics of sentinel lymph nodes' metastatic involvement in early stage of vulvar cancer. *Aust N Z J Obstet Gynaecol* **49**, 672-676 2009.
 120. Achimas-Cadariu, P., *et al.* Assessment of the sentinel lymph node in patients with invasive squamous carcinoma of the vulva. *Acta Obstet Gynecol Scand* **88**, 1209-1214 2009.
 121. Garcia, J.D., *et al.* First results in the sentinel lymph node procedure in vulvar squamous cell carcinoma. *Prog Obstet Gynecol* **52**, 675-680 2009.
 122. Li, B., *et al.* [An initial experience of the use of sentinel lymph node biopsy in squamous cell cancer of the vulva]. *Zhonghua Fu Chan Ke Za Zhi* **44**, 364-368 2009.
 123. Sawicki, S., Romanowicz, G., Wydra, D. & Lass, P. The usefulness of sentinel lymph node detection in vulvar cancer - a short communication. *Nucl Med Rev Cent East Eur* **13**, 81-83 2010.
 124. Radziszewski, J., *et al.* The accuracy of the sentinel lymph node concept in early stage squamous cell vulvar carcinoma. *Gynecol Oncol* **116**, 473-477 2010.
 125. Lindell, G., *et al.* Evaluation of preoperative lymphoscintigraphy and sentinel node procedure in vulvar cancer. *Eur J Obstet Gynecol Reprod Biol* **152**, 91-95 2010.
 126. Crosbie, E.J., *et al.* The accuracy of the sentinel node procedure after excision biopsy in squamous cell carcinoma of the vulva. *Surg Oncol* **19**, e150-154 2010.
 127. Akrivos, N., *et al.* Detection and credibility of sentinel node in vulvar cancer: a single institutional study and short review of literature. *Arch Gynecol Obstet* **284**, 1551-1556 2011.
 128. Guedec-Ghelfi, R., Papathanassiou, D. & Bruna-Muraille, C. Impact of the SPECT/CT in the sentinel lymph node detection. Apropos of 32 cases. *Med Nucl* **35**, 208-218 2011.
 129. Klar, M., *et al.* Sentinel lymph node detection in patients with vulvar carcinoma; Feasibility of intra-operative mapping with technetium-99m-labeled nanocolloid. *Eur J Surg Oncol* **37**, 818-823 2011.
 130. Ennik, T.A., Allen, D.G., Bekkers, R.L., Hyde, S.E. & Grant, P.T. Effects of previous surgery on the detection of sentinel nodes in women with vulvar cancer. *Int J Gynecol Cancer* **21**, 1679-1683 2011.
 131. Crane, L.M., *et al.* Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer:

- first clinical results. *Gynecol Oncol* **120**, 291-295 2011.
132. Devaja, O., *et al.* A prospective study of sentinel lymph node detection in vulval carcinoma: is it time for a change in clinical practice? *Int J Gynecol Cancer* **21**, 559-564 2011.
 133. Woelber, L., *et al.* Secondary sentinel node biopsy after previous excision of the primary tumor in squamous cell carcinoma of the vulva. *Ann Surg Oncol* **20**, 1701-1706 2013.
 134. Hutteman, M., *et al.* Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. *Am J Obstet Gynecol* **206**, 89 e81-85 2012.
 135. Levenback, C.F., *et al.* Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. *J Clin Oncol* **30**, 3786-3791 2012.
 136. Zekan, J., *et al.* Reliability of sentinel node assay in vulvar cancer: the first Croatian validation trial. *Gynecol Oncol* **126**, 99-102 2012.
 137. Garcia-Iglesias, A., *et al.* Sentinel node dissection in the treatment of early stages of vulvar cancer. *Eur J Gynaecol Oncol* **33**, 151-154 2012.
 138. Schaafsma, B.E., *et al.* Near-infrared fluorescence sentinel lymph node biopsy in vulvar cancer: a randomised comparison of lymphatic tracers. *BJOG* **120**, 758-764 2013.
 139. Brunner, A.H., *et al.* The accuracy of intraoperative frozen section of the inguinal sentinel lymph node in vulvar cancer. *Anticancer Res* **28**, 4091-4094 2008.
 140. Camara, O., *et al.* Sentinel lymph node biopsy in vulvar cancer: a pilot study. *Eur J Gynaecol Oncol* **30**, 622-624 2009.
 141. Hauspy, J., *et al.* Sentinel lymph node in vulvar cancer. *Cancer* **110**, 1015-1023 2007.
 142. Levenback, C., *et al.* Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. *Gynecol Oncol* **83**, 276-281 2001.
 143. Martinez-Palones, J.M., *et al.* Comparison of recurrence after vulvectomy and lymphadenectomy with and without sentinel node biopsy in early stage vulvar cancer. *Gynecol Oncol* **103**, 865-870 2006.
 144. Pitynski, K., *et al.* [Lymph node mapping and sentinel node detection in carcinoma of the cervix, endometrium and vulva]. *Ginekolog Pol* **74**, 830-835 2003.
 145. Van der Zee, A.G., *et al.* Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. *J Clin Oncol* **26**, 884-889 2008.
 146. Moore, R.G., *et al.* Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial. *Gynecol Oncol* **109**, 65-70 2008.
 147. Vakselj, A. & Bebar, S. The role of sentinel lymph node detection in vulvar carcinoma and the experiences at the Institute of Oncology Ljubljana. *Radiol Oncol* **41**, 167-173 2007.
 148. Van den Eynden, J., Lannoo, L., Amant, F., Stroobants, S. & Vergote, I. Sentinel node biopsy in the treatment of vulvar cancer. *Tijdschr voor Geneeskunde* **59**, 1169-1178 2003.
 149. Akrivos, N., *et al.* Sentinel node in vulvar cancer. To use or not to use technetium? *Int J Gynecol Cancer* **21**, S905 2011.
 150. De Hullu, J.A., *et al.* Sentinel lymph node identification with technetium-99m-labeled nanocolloid in squamous cell cancer of the vulva. *J Nucl Med* **39**, 1851-1855 1998.

151. Echt, M.L., *et al.* Detection of sentinel lymph nodes with lymphazurin in cervical, uterine, and vulvar malignancies. *South Med J* **92**, 204-208 1999.
152. Goni, E., *et al.* Sentinel lymph node biopsy in vulvar cancer: our experience. *Eur J Nucl Med Mol Imaging* **38**, S368-369 2011.
153. Levenback, C., *et al.* Potential applications of intraoperative lymphatic mapping in vulvar cancer. *Gynecol Oncol* **59**, 216-220 1995.
154. Coleman, R.L., *et al.* When is bilateral lymphadenectomy for midline squamous cell carcinoma of the vulva necessary? An ancillary analysis from GOG-173. *Int J Gynecol Cancer* **21**, S50 2011.
155. Coleman, R.L., *et al.* Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group GOG) 173. *Gynecol Oncol* **128**, 155-159 2013.
156. Levenback, C.F., *et al.* Sentinel node (SN) biopsy in patients with vulvar cancer: a Gynecologic Oncology Group (GOG) study. *J Clin Oncol* **27**, 5505 2009.
157. Louis-Sylvestre, C., *et al.* Sentinel node localization should be interpreted with caution in midline vulvar cancer. *Gynecol Oncol* **97**, 151-154 2005.
158. Martinez-Palones, J.M., *et al.* Comparison of recurrence after vulvectomy and lymphadenectomy with and without sentinel node biopsy in early stage vulvar cancer: Commentary. *Obstet Gynecol Surv* **62**, 240-242 2007.
159. Moore, R.G., *et al.* Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva. *Gynecol Oncol* **89**, 475-479 2003.
160. Morotti, M., *et al.* Role of routine preoperative lymphoscintigraphy in sentinel node biopsy for vulvar cancer. *Int J Gynecol Cancer* **21**, S917 2011.
161. Rob, L., *et al.* [Sentinel lymph nodes identification in vulvar cancer--methods and technique]. *Ceska Gynekol* **71**, 298-301 2006.
162. Sawicki, S., Kobierski, J. & Wydra, D. Sentinel lymph node detection in early vulvar cancer. *Int J Gynecol Cancer* **21**, S935 2011.
163. Wydra, D., Sawicki, S., Emerich, J. & Romanowicz, G. Evaluation of sentinel node detection in vulvar cancer. *Nucl Med Rev Cent East Eur* **8**, 128-130 2005.
164. Trifiro, G., *et al.* Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma. *Eur J Nucl Med Mol Imaging* **37**, 736-741 2010.
165. Puig-Tintore, L.M., *et al.* Further data on the usefulness of sentinel lymph node identification and ultrastaging in vulvar squamous cell carcinoma. *Gynecol Oncol* **88**, 29-34 2003.
166. Vidal-Sicart, S., *et al.* [Sentinel node in gynaecological cancers. Our experience]. *Rev Esp Med Nucl* **28**, 221-228 2009.
167. Vidal-Sicart, S., Puig-Tintore, L.M., Ordi, J. & Lejarcegui, J.A. Localization of sentinel lymph nodes in cancer of the vulva. *Ginecologica y Obstetricia Clinica* **3**, 67-71 2002.
168. Schmidt, E., Zambo, K., Hartmann, T., Dehghani, B. & Bodis, J. Preliminary experiences with sentinel node detection in cases of vulvar malignancy. *Magyar Noorvosok Lapja* **66**, 177-180 2003.
169. Corusic, A., *et al.* Safety of sentinel node biopsy in vulvar cancer FIGO staging IB and II. *Int J Gynecol Cancer* **21**, S900 2011.
170. Oonk, M.H., *et al.* Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. *Lancet Oncol* **11**, 646-652 2010.

171. Brammen, L., *et al.* Sentinel lymph node detection in vulvar cancer patients: a 20 years analysis. *Hell J Nucl Med* **17**, 184-189 2014.
172. Terada, K.Y., Coel, M.N., Ko, P. & Wong, J.H. Combined use of intraoperative lymphatic mapping and lymphoscintigraphy in the management of squamous cell cancer of the vulva. *Gynecol Oncol* **70**, 65-69 1998.
173. Levenback, C.F., *et al.* Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. *Gynecol Oncol* **114**, 151-156 2009.
174. de Hullu, J.A., *et al.* Pitfalls in the sentinel lymph node procedure in vulvar cancer. *Gynecol Oncol* **94**, 10-15 2004.
175. Te Grootenhuis, N.C., *et al.* Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen International Study on Sentinel nodes in Vulvar cancer GROINSS -V) I. *Gynecol Oncol* 2015.
176. Reade, C.J., Jimenez, W., O'Reilly, D. & Covens, A. Sentinel lymph node biopsy in vulvar cancer: a health technology assessment for the canadian health care context. *J Obstet Gynaecol Can* **34**, 1053-1065 2012.
177. de Hullu, J.A., *et al.* Vulvar melanoma: is there a role for sentinel lymph node biopsy? *Cancer* **94**, 486-491 2002.
178. Hefler, L.A., *et al.* Inguinal sentinel lymph node dissection vs. complete inguinal lymph node dissection in patients with vulvar cancer. *Anticancer Res* **28**, 515-517 2008.
179. Gori, J.R., Fritsches, H.W., Castano, R., Toziano, M. & Habich, D. Ipsilateral superficial inguinal lymphadenectomy for the treatment of early cancer of the vulva. *J Low Genit Tract Dis* **6**, 150-154 2002.
180. Frumovitz, M., *et al.* Characteristics of recurrence in patients who underwent lymphatic mapping for vulvar cancer. *Gynecol Oncol* **92**, 205-210 2004.
181. Woolderink, J.M., *et al.* Patterns and frequency of recurrences of squamous cell carcinoma of the vulva. *Gynecol Oncol* **103**, 293-299 2006.
182. Bell, J.G., Lea, J.S. & Reid, G.C. Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma. *Gynecol Oncol* **77**, 314-318 2000.
183. Rodolakis, A., *et al.* Squamous vulvar cancer: a clinically based individualization of treatment. *Gynecol Oncol* **78**, 346-351 2000.
184. Gonzalez Bosquet, J., *et al.* Long-term survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. *Gynecol Oncol* **97**, 828-833 2005.
185. Butler, J.S., *et al.* Isolated groin recurrence in vulval squamous cell cancer VSCC. The importance of node count. *Eur J Gynaecol Oncol* **31**, 510-513 2010.
186. Katz, A., Eifel, P.J., Jhingran, A. & Levenback, C.F. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. *Int J Radiat Oncol Biol Phys* **57**, 409-418 2003.
187. Sznurkowski, J.J. & Emerich, J. Characteristic features of recurrences of squamous cell carcinoma of the vulva. *Ginekol Pol* **81**, 12-19 2010.
188. Canlorbe, G., Rouzier, R., Bendifallah, S. & Chereau, E. [Impact of sentinel node technique on the survival in patients with vulvar cancer: analysis of the Surveillance, Epidemiology, and End Results SEER database]. *Gynecol Obstet Fertil* **40**, 647-651 2012.
189. Gaarenstroom, K.N., *et al.* Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. *Int J Gynecol Cancer* **13**, 522-527 2003.

190. Judson, P.L., *et al.* A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy. *Gynecol Oncol* **95**, 226-230 2004.
191. Carlson, J.W., *et al.* A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. *Gynecol Oncol* **110**, 76-82 2008.
192. Mancini, N., *et al.* Inguinofemoral lymphadenectomy: randomized trial comparing inguinal skin access above or below the inguinal ligament. *Ann Surg Oncol* **16**, 721-728 2009.
193. Sawan, S., Mugnai, R., Lopes Ade, B., Hughes, A. & Edmondson, R.J. Lower-limb lymphedema and vulvar cancer: feasibility of prophylactic compression garments and validation of leg volume measurement. *Int J Gynecol Cancer* **19**, 1649-1654 2009.
194. Gould, N., *et al.* Predictors of complications after inguinal lymphadenectomy. *Gynecol Oncol* **82**, 329-332 2001.
195. Magrina, J.F., *et al.* Primary squamous cell cancer of the vulva: radical versus modified radical vulvar surgery. *Gynecol Oncol* **71**, 116-121 1998.
196. Leminen, A., Forss, M. & Paavonen, J. Wound complications in patients with carcinoma of the vulva. Comparison between radical and modified vulvectomies. *Eur J Obstet Gynecol Reprod Biol* **93**, 193-197 2000.
197. Abbas, S. & Seitz, M. Systematic review and meta-analysis of the used surgical techniques to reduce leg lymphedema following radical inguinal nodes dissection. *Surg Oncol* **20**, 88-96 2011.
198. Oonk, M.H., *et al.* A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. *Gynecol Oncol* **113**, 301-305 2009.
199. Novackova, M., *et al.* A prospective study in the evaluation of quality of life after vulvar cancer surgery. *Int J Gynecol Cancer* **25**, 166-173 2015.
200. Forner, D.M., Dakhil, R. & Lampe, B. Quality of life and sexual function after surgery in early stage vulvar cancer. *Eur J Surg Oncol* **41**, 40-45 2015.
201. de Hullu, J.A., Ansink, A.C., Tymstra, T. & van der Zee, A.G. What doctors and patients think about false-negative sentinel lymph nodes in vulvar cancer. *J Psychosom Obstet Gynaecol* **22**, 199-203 2001.
202. Farrell, R., Gebiski, V. & Hacker, N.F. Quality of life after complete lymphadenectomy for vulvar cancer: do women prefer sentinel lymph node biopsy? *Int J Gynecol Cancer* **24**, 813-819 2014.
203. Covens, A., *et al.* Sentinel lymph node biopsy in vulvar cancer: Systematic review, meta-analysis and guideline recommendations. *Gynecol Oncol* **137**, 351-361 2015.
204. van der Velden, J., Fons, G. & Lawrie, T.A. Primary groin irradiation versus primary groin surgery for early vulvar cancer. *Cochrane Database Syst Rev*, CD002224 2011.
205. Stehman, F.B., *et al.* Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys* **24**, 389-396 1992.
206. Manavi, M., Berger, A., Kucera, E., Vavra, N. & Kucera, H. Does T1, N0-1 vulvar cancer treated by vulvectomy but not lymphadenectomy need inguinofemoral radiation? *Int J Radiat Oncol Biol Phys* **38**, 749-753 1997.
207. Perez, C.A., *et al.* Irradiation in carcinoma of the vulva: factors affecting outcome. *Int J Radiat Oncol Biol Phys* **42**, 335-344 1998.

208. Boronow, R.C., Hickman, B.T., Reagan, M.T., Smith, R.A. & Steadham, R.E. Combined therapy as an alternative to exenteration for locally advanced vulvovaginal cancer. II. Results, complications, and dosimetric and surgical considerations. *Am J Clin Oncol* **10**, 171-181 1987.
209. Balat, O., Edwards, C.L., Verschraegen, C. & Delclos, L. The long term results of radiotherapy with or without surgery in management of advanced vulvar cancer: report of 76 patients. *Eur J Gynaecol Oncol* **21**, 426-429 2000.
210. Rotmensch, J., *et al.* Preoperative radiotherapy followed by radical vulvectomy with inguinal lymphadenectomy for advanced vulvar carcinomas. *Gynecol Oncol* **36**, 181-184 1990.
211. Hacker, N.F., Berek, J.S., Juillard, G.J. & Lagasse, L.D. Preoperative radiation therapy for locally advanced vulvar cancer. *Cancer* **54**, 2056-2061 1984.
212. Jafari, K., Magalotti, F. & Magalotti, M. Radiation therapy in carcinoma of the vulva. *Cancer* **47**, 686-691 1981.
213. Fairey, R.N., MacKay, P.A., Benedet, J.L., Boyes, D.A. & Turko, M. Radiation treatment of carcinoma of the vulva, 1950-1980. *Am J Obstet Gynecol* **151**, 591-597 1985.
214. Carlino, G., Parisi, S., Montemaggi, P. & Pastore, G. Interstitial radiotherapy with Ir192 in vulvar cancer. *Eur J Gynaecol Oncol* **5**, 183-185 1984.
215. Pao, W.M., *et al.* Radiation therapy and conservation surgery for primary and recurrent carcinoma of the vulva: report of 40 patients and a review of the literature. *Int J Radiat Oncol Biol Phys* **14**, 1123-1132 1988.
216. Faul, C.M., *et al.* Adjuvant radiation for vulvar carcinoma: improved local control. *Int J Radiat Oncol Biol Phys* **38**, 381-389 1997.
217. Fons, G., *et al.* Adjuvant radiotherapy in patients with vulvar cancer and one intra capsular lymph node metastasis is not beneficial. *Gynecol Oncol* **114**, 343-345 2009.
218. Mahner, S., *et al.* Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. *J Natl Cancer Inst* **107**2015.
219. Parthasarathy, A., *et al.* The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma. *Gynecol Oncol* **103**, 1095-1099 2006.
220. Homesley, H.D., Bundy, B.N., Sedlis, A. & Adcock, L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. *Obstet Gynecol* **68**, 733-740 1986.
221. Kunos, C., Simpkins, F., Gibbons, H., Tian, C. & Homesley, H. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. *Obstet Gynecol* **114**, 537-546 2009.
222. Shylasree, T.S., Bryant, A. & Howells, R.E. Chemoradiation for advanced primary vulval cancer. *Cochrane Database Syst Rev*, CD003752 2011.
223. Maneo, A., Landoni, F., Colombo, A., Villa, A. & Caspani, G. Randomised study between neoadjuvant chemoradiotherapy and primary surgery for the treatment of advanced vulval cancer. *Int J Gynecol Cancer* **13 Suppl 1** , Abstract PL 19 2003.
224. Landrum, L.M., Skaggs, V., Gould, N., Walker, J.L. & McMeekin, D.S. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. *Gynecol Oncol* **108**, 584-590 2008.
225. Mulayim, N., Foster Silver, D., Schwartz, P.E. & Higgins, S. Chemoradiation with 5-fluorouracil and mitomycin C in the treatment of vulvar squamous cell

- carcinoma. *Gynecol Oncol* **93**, 659-666 2004.
226. Moore, D.H., *et al.* A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. *Gynecol Oncol* **124**, 529-533 2012.
 227. Sebag-Montefiore, D.J., *et al.* Treatment of advanced carcinoma of the vulva with chemoradiotherapy - can exenterative surgery be avoided? *Int J Gynecol Cancer* **4**, 150-155 1994.
 228. Tans, L., Ansink, A.C., van Rooij, P.H., Kleijnen, C. & Mens, J.W. The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. *Am J Clin Oncol* **34**, 22-26 2011.
 229. Russell, A.H., *et al.* Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva. *Gynecol Oncol* **47**, 14-20 1992.
 230. Thomas, G., *et al.* Concurrent radiation and chemotherapy in vulvar carcinoma. *Gynecol Oncol* **34**, 263-267 1989.
 231. Mak, R.H., *et al.* Outcomes after radiation therapy with concurrent weekly platinum-based chemotherapy or every-3-4-week 5-fluorouracil-containing regimens for squamous cell carcinoma of the vulva. *Gynecol Oncol* **120**, 101-107 2011.
 232. Leiserowitz, G.S., *et al.* Prophylactic chemoradiation of inguinofemoral lymph nodes in patients with locally extensive vulvar cancer. *Gynecol Oncol* **66**, 509-514 1997.
 233. Koh, W.J., *et al.* Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. *Int J Radiat Oncol Biol Phys* **26**, 809-816 1993.
 234. Wahlen, S.A., *et al.* Concurrent radiation therapy and chemotherapy in the treatment of primary squamous cell carcinoma of the vulva. *Cancer* **75**, 2289-2294 1995.
 235. Cunningham, M.J., *et al.* Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. *Gynecol Oncol* **66**, 258-261 1997.
 236. Han, S.C., Kim, D.H., Higgins, S.A., Carcangiu, M.L. & Kacinski, B.M. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. *Int J Radiat Oncol Biol Phys* **47**, 1235-1244 2000.
 237. Berek, J.S., Heaps, J.M., Fu, Y.S., Juillard, G.J. & Hacker, N.F. Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. *Gynecol Oncol* **42**, 197-201 1991.
 238. Iversen, T. Irradiation and bleomycin in the treatment of inoperable vulval carcinoma. *Acta Obstet Gynecol Scand* **61**, 195-197 1982.
 239. Akl, A., Akl, M., Boike, G., Hebert, J. & Graham, J. Preliminary results of chemoradiation as a primary treatment for vulvar carcinoma. *Int J Radiat Oncol Biol Phys* **48**, 415-420 2000.
 240. Evans, L.S., Kersh, C.R., Constable, W.C. & Taylor, P.T. Concomitant 5-fluorouracil, mitomycin-C, and radiotherapy for advanced gynecologic malignancies. *Int J Radiat Oncol Biol Phys* **15**, 901-906 1988.
 241. Kalra, J., *et al.* Effective multimodality treatment for advanced epidermoid carcinoma of the female genital tract. *J Clin Oncol* **3**, 917-924 1985.
 242. Beriwal, S., *et al.* Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse. *Int J Radiat Oncol Biol Phys* **85**, 1269-1274 2013.

243. Moore, D.H., *et al.* Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. *Int J Radiat Oncol Biol Phys* **42**, 79-85 1998.
244. Landoni, F., *et al.* Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy FUMIR followed by limited surgery in locally advanced and recurrent vulvar carcinoma. *Gynecol Oncol* **61**, 321-327 1996.
245. Eifel, P.J., Morris, M., Burke, T.W., Levenback, C. & Gershenson, D.M. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. *Gynecol Oncol* **59**, 51-56 1995.
246. Whitaker, S.J., Kirkbride, P., Arnott, S.J., Hudson, C.N. & Shepherd, J.H. A pilot study of chemo-radiotherapy in advanced carcinoma of the vulva. *Br J Obstet Gynaecol* **97**, 436-442 1990.
247. Levin, W., Goldberg, G., Altaras, M., Bloch, B. & Shelton, M.G. The use of concomitant chemotherapy and radiotherapy prior to surgery in advanced stage carcinoma of the vulva. *Gynecol Oncol* **25**, 20-25 1986.
248. Beriwal, S., *et al.* Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. *Int J Radiat Oncol Biol Phys* **64**, 1395-1400 2006.
249. Stuckey, A., Schutzer, M., Rizack, T. & Dizon, D. Locally advanced vulvar cancer in elderly women: is chemoradiation beneficial? *Am J Clin Oncol* **36**, 279-282 2013.
250. Montana, G.S., *et al.* Preoperative chemoradiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study. *Int J Radiat Oncol Biol Phys* **48**, 1007-1013 2000.
251. Scheistroen, M. & Trope, C. Combined bleomycin and irradiation in preoperative treatment of advanced squamous cell carcinoma of the vulva. *Acta Oncol* **32**, 657-661 1993.
252. Lupi, G., *et al.* Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. A pilot study. *Cancer* **77**, 1472-1478 1996.
253. Gaudineau, A., *et al.* Neoadjuvant chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the vulva. *Oncol Lett* **4**, 719-722 2012.
254. Gerszten, K., Selvaraj, R.N., Kelley, J. & Faul, C. Preoperative chemoradiation for locally advanced carcinoma of the vulva. *Gynecol Oncol* **99**, 640-644 2005.
255. Carson, L.F., Twigg, L.B., Adcock, L.L., Prem, K.A. & Potish, R.A. Multimodality therapy for advanced and recurrent vulvar squamous cell carcinoma. A pilot project. *J Reprod Med* **35**, 1029-1032 1990.
256. Gill, B.S., *et al.* Impact of adjuvant chemotherapy with radiation for node-positive vulvar cancer: A National Cancer Data Base NCD B analysis. *Gynecol Oncol* **137**, 365-372 2015.
257. Durrant, K.R., *et al.* Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG). *Gynecol Oncol* **37**, 359-362 1990.
258. Benedetti-Panici, P., Greggi, S., Scambia, G., Salerno, G. & Mancuso, S. Cisplatin P, bleomycin B, and methotrexate M preoperative chemotherapy in locally advanced vulvar carcinoma. *Gynecol Oncol* **50**, 49-53 1993.
259. Wagenaar, H.C., *et al.* Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. *Gynecol Oncol* **81**, 348-354 2001.

260. Bafna, U.D., *et al.* Carcinoma of the vulva: a retrospective review of 37 cases at a regional cancer centre in South India. *J Obstet Gynaecol* **24**, 403-407 2004.
261. Geisler, J.P., Manahan, K.J. & Buller, R.E. Neoadjuvant chemotherapy in vulvar cancer: avoiding primary exenteration. *Gynecol Oncol* **100**, 53-57 2006.
262. Domingues, A.P., *et al.* Neoadjuvant chemotherapy in advanced vulvar cancer. *Int J Gynecol Cancer* **20**, 294-298 2010.
263. Aragona, A.M., *et al.* Tailoring the treatment of locally advanced squamous cell carcinoma of the vulva: neoadjuvant chemotherapy followed by radical surgery: results from a multicenter study. *Int J Gynecol Cancer* **22**, 1258-1263 2012.
264. Han, S.N., Vergote, I. & Amant, F. Weekly paclitaxel/carboplatin in the treatment of locally advanced, recurrent, or metastatic vulvar cancer. *Int J Gynecol Cancer* **22**, 865-868 2012.
265. Bellati, F., *et al.* Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. *Gynecol Oncol* **96**, 227-231 2005.
266. Horowitz, N.S., *et al.* Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. *Gynecol Oncol* **127**, 141-146 2012.
267. Witteveen, P.O., *et al.* Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG European Organisation for Research and Treatment of Cancer--Gynaecological Cancer Group. *Ann Oncol* **20**, 1511-1516 2009.
268. Thigpen, J.T., Blessing, J.A., Homesley, H.D. & Lewis, G.C., Jr. Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study. *Gynecol Oncol* **23**, 358-363 1986.
269. Cormio, G., *et al.* Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma. *Oncology* **77**, 281-284 2009.
270. Muss, H.B., Bundy, B.N. & Christopherson, W.A. Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A gynecologic oncology group study. *Am J Clin Oncol* **12**, 142-144 1989.
271. Salani, R., *et al.* Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. *Am J Obstet Gynecol* **204**, 466-478 2011.

18 Appendices

18.1 Appendix 1 - List of the international development group

Name	Specialty	Affiliation
Ate van der Zee	Gynecologic Oncologist chair	University Medical Center, Groningen Netherlands)
Maaïke Oonk	Gynecologic Oncologist co-chair	University Medical Center, Groningen Netherlands)
François Planchamp	Methodologist	Institut Bergonié, Bordeaux France
Peter Baldwin	Gynecologic Oncologist	Addenbrooke's Hospital, Cambridge United Kingdom
Mariusz Bidzinski	Gynecologic Oncologist	Hollycross Oncology Center, Kielce Poland
Mats Brännström	Gynecologic Oncologist	University of Göteborg, Göteborg Sweden
Fabio Landoni	Gynecologic Oncologist	European Institute of Oncology, Milano Italy
Sven Mahner	Gynecologic Oncologist	University of Munich, Munich Germany
Sergio Martinez	Gynecologic Oncologist	Hospital Clinic, Barcelona Spain
Umesh Mahantshetty	Radiation Oncologist	Tata Memorial Hospital, Mumbai India
Mansoor Mirza	Medical Oncologist	Finsen Centre, Rigshospitalet, Copenhagen Denmark
Cordula Petersen	Radiation Oncologist	University Medical Center, Hambourg Germany
Sigrid Regauer	Pathologist	Medical University, Graz Austria
Lukas Rob	Gynecologic Oncologist	Charles University , Prague Czech Republic
Roman Rouzier	Surgeon	Pierre and Marie Curie University, Paris France
Elena Ulrikh	Gynecologic Oncologist	St. Petersburg N.N Petrov Research Institut, St. Petersburg Russia
Jacobus van der Velden	Gynecologic Oncologist	Academic Medical Center, Amsterdam Netherlands)
Ignace Vergote	Gynecologic Oncologist	University Hospital, Leuven Belgium
Linn Woelber	Gynecologic Oncologist	University Clinic, Hamburg Germany

18.2 Appendix 2 - List of evidence-based medicine websites consulted

Organism/agency	Website
ACPG	http://www.topalbertadoctors.org/home/
AGDH	http://www.health.gov.au/
AHRQ	http://www.guideline.gov/
AQuAS	http://aquas.gencat.cat/ca/
ASCO	http://www.asco.org/
BCCA	http://www.bccancer.bc.ca/default.htm
CADTH	http://www.cadth.ca/
CCO	https://www.cancercare.on.ca/
CEPO	http://www.msss.gouv.qc.ca/index.php
CoCanCPG	http://www.cocancpg.eu/
COMPAQ-HPST	http://www.compaqhpst.fr/fr/
ESMO	http://www.esmo.org/
GIN	http://www.g-i-n.net/
HAS	http://www.has-sante.fr/portail/jcms/fc_1249588/fr/accueil
INAHTA	http://www.inahta.org/
INCa	http://www.e-cancer.fr/
INESSS	http://www.inesss.qc.ca/
KCE	https://kce.fgov.be/fr
MSAC	http://www.msac.gov.au/
NCCN	http://www.nccn.org/
NHMRC	http://www.nhmrc.gov.au/
NHS	http://www.nhs.uk/Pages/HomePage.aspx
NICE	http://www.nice.org.uk/
NZGG	http://www.health.govt.nz/
SIGN	http://www.sign.ac.uk/

ACPG Alberta Clinical Practice Guidelines, AGDH Australian Government Department of Health, AHRQ Agency for Healthcare Research and Quality, AQuAS Agència de Qualitat i Avaluació Sanitàries de Catalunya, ASCO American Society of Clinical Oncology BCCA British Columbia Cancer Agency, CADTH Canadian Agency for Drugs and Technologies in Health, CCO Cancer Care Ontario, CEPO Comité de l'Évolution des Pratiques en Oncologie, CoCanCPG Coordination of Cancer Clinical Practice Guidelines in Europe, COMPAQ-HPST Coordination pour la Mesure de la Performance et l'Amélioration de la Qualité, Hôpital, Patient, Sécurité, Territoire, ESMO European Society of Medical Oncology, GIN Guidelines International Network, HAS Haute Autorité de santé, INAHTA International Network of Agencies for Health Technology Assessment, INCa Institut National du Cancer, INESSS Institut National d'Excellence en Santé et en Services Sociaux, KCE Centre fédéral d'expertise des soins de santé, MSAC Medical Services Advisory Committee, NCCN National Comprehensive Cancer Network, NHMRC National Health and Medical Research Council, NHS National Health Service, NICE National Institute for Health and Care Excellence, NZGG New Zealand Guidelines Group, SIGN Scottish Intercollegiate Guidelines Network.

18.3 Appendix 3 - Key to evidence statements and grades of recommendations⁵

LEVELS OF EVIDENCE

1++	High quality meta-analyses, systematic reviews of randomized controlled trials RCT s, or RCTs with a very low risk of bias
1+	Well conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias
1-	Meta-analyses, systematic reviews, or RCTs with a high risk of bias
2++	High quality systematic reviews of case control or cohort studies High quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal
2+	Well conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
2-	Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3	Non-analytic studies, eg case reports, case series
4	Expert opinion

GRADES OF RECOMMENDATIONS

A	At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
B	A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+
C	A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or Extrapolated evidence from studies rates as 2++
D	Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+

GOOD PRACTICE POINTS

✓	Recommended best practice based on the clinical experience of the guideline development group
---	---

⁵ <http://www.sign.ac.uk/guidelines/fulltext/50/annexoldb.html>



European Society of
Gynaecological Oncology

ESGO Office
c/o CoWorking Prague
Karlovo nám. 7/325
120 00 Prague, Czech Republic
Email: adminoffice@esgomail.org

www.esgo.org



The European Voice of Gynaecological Oncology